PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26377606-3 2016 The aim of this study was to characterize the fluctuations in the levels of natural anticoagulants, particularly TFPI, in the course of sepsis and to find out their association with the anticoagulant action of the low-molecular-weight heparin enoxaparin. Heparin 235-242 tissue factor pathway inhibitor Homo sapiens 113-117 30194803-10 2018 Results Mouse TFPI and human TFPI are similar in regard to: (i) the mechanisms for FVIIa/TF and FXa inhibition; (ii) TFPIalpha is a soluble form and TFPIbeta is glycosyl phosphatidyl inositol (GPI) membrane anchored; (iii) the predominant circulating form of TFPI in plasma is lipoprotein-associated; (iv) low levels of TFPIalpha circulate in plasma and increase following heparin treatment; and (v) TFPIalpha is the isoform in platelets. Heparin 373-380 tissue factor pathway inhibitor Homo sapiens 29-33 27566697-3 2016 Aims of the present study are (1) to evaluate a possible role of low-molecular-weight-heparins (LMWHs) in the modulation of the expression of TF, TFPI, TFPI2 and VEGF in placentae from thrombophilic women and (2) to study the possible role of endothelium in the placental expression of markers involved in haemostasis and angiogenesis. Heparin 86-94 tissue factor pathway inhibitor Homo sapiens 146-150 30194803-10 2018 Results Mouse TFPI and human TFPI are similar in regard to: (i) the mechanisms for FVIIa/TF and FXa inhibition; (ii) TFPIalpha is a soluble form and TFPIbeta is glycosyl phosphatidyl inositol (GPI) membrane anchored; (iii) the predominant circulating form of TFPI in plasma is lipoprotein-associated; (iv) low levels of TFPIalpha circulate in plasma and increase following heparin treatment; and (v) TFPIalpha is the isoform in platelets. Heparin 373-380 tissue factor pathway inhibitor Homo sapiens 29-33 30086574-8 2018 RESULTS/CONCLUSION: The most striking changes were observed following heparin administration and were associated with the appearance of inactive forms of anti-thrombin and an increase in the plasma concentration of TFPI. Heparin 71-78 tissue factor pathway inhibitor Homo sapiens 216-220 26607136-12 2016 Direct FXa inhibition by TFPI is modulated by physiological concentrations prothrombin, FV, FVa, protein S, phospholipids and heparin indicating the importance of these modulators for the in vivo anticoagulant activity of TFPI. Heparin 126-133 tissue factor pathway inhibitor Homo sapiens 25-29 26607136-2 2016 Both TFPI and FXa interact with several plasma proteins (e. g. prothrombin, FV/FVa, protein S) and non-proteinaceous compounds (e. g. phospholipids, heparin). Heparin 149-156 tissue factor pathway inhibitor Homo sapiens 5-9 19218095-6 2009 Increasing concentrations (0-200 ng/mL) of various TFPI in the presence of low heparin concentrations (0.1 IU/mL) prolonged lag time and decreased ETP by 25% to 75% with the most prominent effect promoted by glycosylated full-length TFPI. Heparin 79-86 tissue factor pathway inhibitor Homo sapiens 51-55 26607136-6 2016 Unfractionated heparin at concentrations (0.2-1 U/ml) enhanced FXa inhibition by TFPI ~8-fold, but impaired inhibition at concentrations > 1 U/ml. Heparin 15-22 tissue factor pathway inhibitor Homo sapiens 81-85 23320987-6 2013 Cell-associated TFPI was detected after phosphatidylinositol-phospholipase C (PI-PLC) and heparin treatment by flow cytometry, immunofluorescence, and Western blotting. Heparin 90-97 tissue factor pathway inhibitor Homo sapiens 16-20 22302552-0 2012 Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients. Heparin 10-17 tissue factor pathway inhibitor Homo sapiens 29-33 22302552-5 2012 Heparin-releasable free FL TFPI was determined in a random subset of 17 patients and 15 controls. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 27-31 22302552-8 2012 However, levels of heparin-releasable free FL TFPI were higher in patients than in controls. Heparin 19-26 tissue factor pathway inhibitor Homo sapiens 46-50 22302552-9 2012 CONCLUSIONS: Although ambient plasma levels of total TFPI were not different in subtypes of LS, the increased levels of heparin-releasable TFPI in patients suggest a role of endothelial activation in the pathogenesis of LS. Heparin 120-127 tissue factor pathway inhibitor Homo sapiens 139-143 20880110-2 2010 This study explores the UFH-dependent tissue factor pathway inhibitor (TFPI) release in children compared to previously published data in adults. Heparin 24-27 tissue factor pathway inhibitor Homo sapiens 71-75 20880110-5 2010 This study demonstrated that, whilst the immediate release of TFPI post-UFH was similar in children compared to adults, TFPI release in children remained increased and consistent for a significantly longer period post-UFH administration compared to adults. Heparin 72-75 tissue factor pathway inhibitor Homo sapiens 62-66 20880110-7 2010 The prolonged TFPI-mediated anticoagulant levels observed in children administered UFH may contribute to the increased rate of major bleeding reported in children compared to adults. Heparin 83-86 tissue factor pathway inhibitor Homo sapiens 14-18 20880110-8 2010 Furthermore, we postulate that this sustained UFH-dependent increase in TFPI levels in children may influence the binding of UFH to competitive plasma proteins, such as those involved in the immunological response to UFH associated with heparin-induced thrombocytopenia. Heparin 46-49 tissue factor pathway inhibitor Homo sapiens 72-76 20880110-8 2010 Furthermore, we postulate that this sustained UFH-dependent increase in TFPI levels in children may influence the binding of UFH to competitive plasma proteins, such as those involved in the immunological response to UFH associated with heparin-induced thrombocytopenia. Heparin 125-128 tissue factor pathway inhibitor Homo sapiens 72-76 20880110-8 2010 Furthermore, we postulate that this sustained UFH-dependent increase in TFPI levels in children may influence the binding of UFH to competitive plasma proteins, such as those involved in the immunological response to UFH associated with heparin-induced thrombocytopenia. Heparin 125-128 tissue factor pathway inhibitor Homo sapiens 72-76 20880110-8 2010 Furthermore, we postulate that this sustained UFH-dependent increase in TFPI levels in children may influence the binding of UFH to competitive plasma proteins, such as those involved in the immunological response to UFH associated with heparin-induced thrombocytopenia. Heparin 237-244 tissue factor pathway inhibitor Homo sapiens 72-76 20592020-1 2010 Tissue factor pathway inhibitor (TFPI) inhibits tissue factor-induced coagulation, but may, via its C terminus, also modulate cell surface, heparin, and lipopolysaccharide interactions as well as participate in growth inhibition. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 0-31 20592020-1 2010 Tissue factor pathway inhibitor (TFPI) inhibits tissue factor-induced coagulation, but may, via its C terminus, also modulate cell surface, heparin, and lipopolysaccharide interactions as well as participate in growth inhibition. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 33-37 19285275-10 2009 As heparins are strong inhibitors of heparanase, in view of the effect of heparanase on the TF/TFPI pathway, the role of anticoagulant activity of heparin may potentially be expanded. Heparin 3-11 tissue factor pathway inhibitor Homo sapiens 95-99 19285275-10 2009 As heparins are strong inhibitors of heparanase, in view of the effect of heparanase on the TF/TFPI pathway, the role of anticoagulant activity of heparin may potentially be expanded. Heparin 3-10 tissue factor pathway inhibitor Homo sapiens 95-99 24266905-1 2014 BACKGROUND: We tested the hypothesis that heparin administration prior to the emergence of tissue factor (TF) would increase plasma TF pathway inhibitor (TFPI) and attenuate TF-mediated thrombin generation during simulated cardiopulmonary bypass (CPB). Heparin 42-49 tissue factor pathway inhibitor Homo sapiens 132-152 24266905-1 2014 BACKGROUND: We tested the hypothesis that heparin administration prior to the emergence of tissue factor (TF) would increase plasma TF pathway inhibitor (TFPI) and attenuate TF-mediated thrombin generation during simulated cardiopulmonary bypass (CPB). Heparin 42-49 tissue factor pathway inhibitor Homo sapiens 154-158 24266905-4 2014 In the two TFPI boost groups, 50 U/kg of heparin was given to the donors intravenously five minutes before donation to boost plasma TFPI levels. Heparin 41-48 tissue factor pathway inhibitor Homo sapiens 11-15 24266905-4 2014 In the two TFPI boost groups, 50 U/kg of heparin was given to the donors intravenously five minutes before donation to boost plasma TFPI levels. Heparin 41-48 tissue factor pathway inhibitor Homo sapiens 132-136 24266905-8 2014 The heparin-induced TFPI elevation reduced both thrombin-antithrombin complex and F1+2 to control levels in rTF + TFPI boost group (p = 0.0158 for thrombin-antithrombin complex, p < 0.0001 for F1+2 ). Heparin 4-11 tissue factor pathway inhibitor Homo sapiens 20-24 24266905-8 2014 The heparin-induced TFPI elevation reduced both thrombin-antithrombin complex and F1+2 to control levels in rTF + TFPI boost group (p = 0.0158 for thrombin-antithrombin complex, p < 0.0001 for F1+2 ). Heparin 4-11 tissue factor pathway inhibitor Homo sapiens 114-118 24266905-10 2014 CONCLUSIONS: Heparin-induced TFPI elevation attenuates TF-mediated thrombin generation. Heparin 13-20 tissue factor pathway inhibitor Homo sapiens 29-33 21162606-10 2010 The peak activity for the TFPI effect was earlier than the anti-Xa effect, at 1-2 h, and lasted for 6-12 h. Bemiparin thus has good antithrombotic activity and a better pharmacological profile than unfractionated heparin. Heparin 213-220 tissue factor pathway inhibitor Homo sapiens 26-30 19959490-8 2010 Topical administration of both the MPS and heparin ointments resulted in no measurable anticoagulant effects in the primate model; however, MPS produced a concentration-dependent release of TFPI antigen and a functional activity that was stronger than the effects observed with heparin. Heparin 278-285 tissue factor pathway inhibitor Homo sapiens 190-194 19736157-4 2009 UFH released tissue factor pathway inhibitor (TFPI) during and immediately after PCI while bivalirudin (irrespective of GP IIb/IIIa) did not. Heparin 0-3 tissue factor pathway inhibitor Homo sapiens 13-44 19736157-4 2009 UFH released tissue factor pathway inhibitor (TFPI) during and immediately after PCI while bivalirudin (irrespective of GP IIb/IIIa) did not. Heparin 0-3 tissue factor pathway inhibitor Homo sapiens 46-50 19218095-11 2009 The C-terminal region and, to a lesser extent, glycosylation of the TFPI molecule were essential for its anticoagulant function in the absence and presence of heparin. Heparin 159-166 tissue factor pathway inhibitor Homo sapiens 68-72 19731406-1 2009 PURPOSE: Anticoagulant tissue factor pathway inhibitor (TFPI) is released from its endothelial stores by heparin, which may lead to its untoward depletion. Heparin 105-112 tissue factor pathway inhibitor Homo sapiens 23-54 19731406-1 2009 PURPOSE: Anticoagulant tissue factor pathway inhibitor (TFPI) is released from its endothelial stores by heparin, which may lead to its untoward depletion. Heparin 105-112 tissue factor pathway inhibitor Homo sapiens 56-60 18645924-10 2008 As heparins are strong inhibitors of heparanase, in view of the effect of heparanase on TF/TFPI pathway, the role of heparins" anticoagulant activity may potentially be expanded. Heparin 3-11 tissue factor pathway inhibitor Homo sapiens 91-95 18716314-1 2008 Low-molecular-weight heparins (LMWHs) differ considerably in their influence on clotting tests and release of tissue factor pathway inhibitor (TFPI). Heparin 21-29 tissue factor pathway inhibitor Homo sapiens 110-141 18716314-1 2008 Low-molecular-weight heparins (LMWHs) differ considerably in their influence on clotting tests and release of tissue factor pathway inhibitor (TFPI). Heparin 21-29 tissue factor pathway inhibitor Homo sapiens 143-147 18160611-0 2008 Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid--anchored forms of tissue factor pathway inhibitor. Heparin 25-32 tissue factor pathway inhibitor Homo sapiens 102-133 18160611-1 2008 The release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) was investigated using heparin and phospholipase C. The experiment included incubating HUVECs with 0, 1, or 10 U/mL heparin diluted in Dulbecco Modified Eagle"s Medium plus 5% fetal calf serum for 1 or 24 hours. Heparin 130-137 tissue factor pathway inhibitor Homo sapiens 15-46 18160611-1 2008 The release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) was investigated using heparin and phospholipase C. The experiment included incubating HUVECs with 0, 1, or 10 U/mL heparin diluted in Dulbecco Modified Eagle"s Medium plus 5% fetal calf serum for 1 or 24 hours. Heparin 130-137 tissue factor pathway inhibitor Homo sapiens 48-52 18160611-1 2008 The release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) was investigated using heparin and phospholipase C. The experiment included incubating HUVECs with 0, 1, or 10 U/mL heparin diluted in Dulbecco Modified Eagle"s Medium plus 5% fetal calf serum for 1 or 24 hours. Heparin 223-230 tissue factor pathway inhibitor Homo sapiens 15-46 18160611-1 2008 The release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) was investigated using heparin and phospholipase C. The experiment included incubating HUVECs with 0, 1, or 10 U/mL heparin diluted in Dulbecco Modified Eagle"s Medium plus 5% fetal calf serum for 1 or 24 hours. Heparin 223-230 tissue factor pathway inhibitor Homo sapiens 48-52 18160611-4 2008 Sequential treatment of HUVECs with phospholipase C and heparin was performed, and a trend was observed where GPI-anchored TFPI levels were increased after 1 hour of pretreatment with heparin but were decreased after 24 hours. Heparin 56-63 tissue factor pathway inhibitor Homo sapiens 123-127 18160611-4 2008 Sequential treatment of HUVECs with phospholipase C and heparin was performed, and a trend was observed where GPI-anchored TFPI levels were increased after 1 hour of pretreatment with heparin but were decreased after 24 hours. Heparin 184-191 tissue factor pathway inhibitor Homo sapiens 123-127 18160611-5 2008 Serum is a requirement for the heparin-dependent release of TFPI from HUVECs. Heparin 31-38 tissue factor pathway inhibitor Homo sapiens 60-64 18160611-6 2008 Heparin pretreatment of HUVECs may affect levels of GPI anchored TFPI in a time and dose-dependent manner. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 65-69 17376263-5 2007 Blame had been laid on the combined use of heparin or low molecular weight heparin (LMWH), as it might interfere with efficacy of antithrombin and TFPI. Heparin 43-50 tissue factor pathway inhibitor Homo sapiens 147-151 18261960-6 2008 Studies of cultured endothelial cells and human placenta have demonstrated that TFPI associates with the cell surface through a glycosyl phosphatidyinositol (GPI)-anchor in a manner that is not dependent on GAGs or altered by heparin. Heparin 226-233 tissue factor pathway inhibitor Homo sapiens 80-84 17376263-5 2007 Blame had been laid on the combined use of heparin or low molecular weight heparin (LMWH), as it might interfere with efficacy of antithrombin and TFPI. Heparin 75-82 tissue factor pathway inhibitor Homo sapiens 147-151 16824584-0 2007 Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Heparin 70-77 tissue factor pathway inhibitor Homo sapiens 27-58 16824584-1 2007 Heparin and low molecular weight heparins exert their vascular effects by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 85-116 16919311-6 2007 RESULTS: Stimulation of Ea.hy 926 cells with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) caused a time- and dose-dependent upregulation of TFPI-mRNA expression with LMWH showing the stronger effect. Heparin 98-105 tissue factor pathway inhibitor Homo sapiens 163-167 16919311-2 2007 In this study we examined the in vitro effects of heparin and other glycosaminoglycans on TFPI mRNA-expression in cultivated human endothelial (Ea.hy 926) and in chondrosarcoma (SW 1353) cells. Heparin 50-57 tissue factor pathway inhibitor Homo sapiens 90-94 16824584-1 2007 Heparin and low molecular weight heparins exert their vascular effects by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 118-122 16919311-10 2007 As a conclusion, the determined heparin-induced upregulation of TFPI-mRNA expression can be considered a major component of the modulation of the anticoagulant properties of the endothelium. Heparin 32-39 tissue factor pathway inhibitor Homo sapiens 64-68 16824584-1 2007 Heparin and low molecular weight heparins exert their vascular effects by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 33-41 tissue factor pathway inhibitor Homo sapiens 85-116 16919311-6 2007 RESULTS: Stimulation of Ea.hy 926 cells with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) caused a time- and dose-dependent upregulation of TFPI-mRNA expression with LMWH showing the stronger effect. Heparin 60-67 tissue factor pathway inhibitor Homo sapiens 163-167 16824584-1 2007 Heparin and low molecular weight heparins exert their vascular effects by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 33-41 tissue factor pathway inhibitor Homo sapiens 118-122 16919311-6 2007 RESULTS: Stimulation of Ea.hy 926 cells with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) caused a time- and dose-dependent upregulation of TFPI-mRNA expression with LMWH showing the stronger effect. Heparin 69-72 tissue factor pathway inhibitor Homo sapiens 163-167 16824584-2 2007 We compared the influence of molecular weight on the TFPI release by heparin and its fractions in a non-human primate model. Heparin 69-76 tissue factor pathway inhibitor Homo sapiens 53-57 16520718-0 2006 Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. Heparin 153-160 tissue factor pathway inhibitor Homo sapiens 58-89 16689752-3 2006 Upon heparin infusion during cardiopulmonary bypass (CPB), a heparin releasable pool of endothelial associated TFPI circulates in plasma. Heparin 5-12 tissue factor pathway inhibitor Homo sapiens 111-115 16689752-3 2006 Upon heparin infusion during cardiopulmonary bypass (CPB), a heparin releasable pool of endothelial associated TFPI circulates in plasma. Heparin 61-68 tissue factor pathway inhibitor Homo sapiens 111-115 16689752-4 2006 Following protamine neutralization of heparin, the plasma TFPI level decreases, but does not return completely to baseline, suggesting that during CPB a fraction of the plasma TFPI becomes heparin-independent. Heparin 38-45 tissue factor pathway inhibitor Homo sapiens 58-62 16689752-4 2006 Following protamine neutralization of heparin, the plasma TFPI level decreases, but does not return completely to baseline, suggesting that during CPB a fraction of the plasma TFPI becomes heparin-independent. Heparin 38-45 tissue factor pathway inhibitor Homo sapiens 176-180 16689752-11 2006 RESULTS: The ELISA and Western blot data indicated that an increase in full-length TFPI accounted for most of the heparin releasable TFPI. Heparin 114-121 tissue factor pathway inhibitor Homo sapiens 83-87 16689752-11 2006 RESULTS: The ELISA and Western blot data indicated that an increase in full-length TFPI accounted for most of the heparin releasable TFPI. Heparin 114-121 tissue factor pathway inhibitor Homo sapiens 133-137 16689752-12 2006 Following heparin neutralization with protamine, the full-length TFPI antigen returned to baseline levels while the free TFPI antigen and the total plasma TFPI activity remained elevated. Heparin 10-17 tissue factor pathway inhibitor Homo sapiens 65-69 16689752-16 2006 CONCLUSIONS: During CPB the full-length form of TFPI is the predominant form in plasma because of its prompt release from the endothelial surface following heparin administration. Heparin 156-163 tissue factor pathway inhibitor Homo sapiens 48-52 16689752-17 2006 Upon heparin neutralization with protamine, full-length TFPI redistributes back to the endothelial surface. Heparin 5-12 tissue factor pathway inhibitor Homo sapiens 56-60 16520718-1 2006 AIM: The effects of C-reactive protein (CRP) and low molecular weight heparin (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) were examined. Heparin 70-77 tissue factor pathway inhibitor Homo sapiens 103-134 16520718-1 2006 AIM: The effects of C-reactive protein (CRP) and low molecular weight heparin (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) were examined. Heparin 70-77 tissue factor pathway inhibitor Homo sapiens 136-140 16520718-8 2006 The amount of endothelial TFPI released was dependent on the heparin molecular weight distribution, with minimal effect at 3000 Da and maximum at 8000 to 12,000 Da. Heparin 61-68 tissue factor pathway inhibitor Homo sapiens 26-30 16461305-8 2006 Both heparins increased TFPI antigen release in HMEC-1 and HUVEC. Heparin 5-13 tissue factor pathway inhibitor Homo sapiens 24-28 15678271-0 2005 Comparative tissue factor pathway inhibitor release potential of heparins. Heparin 65-73 tissue factor pathway inhibitor Homo sapiens 12-43 15876997-0 2005 Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. Heparin 48-55 tissue factor pathway inhibitor Homo sapiens 134-165 15876997-1 2005 AIM: Pharmacodynamic effects of the low molecular weight heparin tinzaparin on plasma levels of tissue factor pathway inhibitor (TFPI) and nitric oxide (NO) were compared in obese subjects, as well as in normal healthy controls. Heparin 57-64 tissue factor pathway inhibitor Homo sapiens 96-127 15678271-1 2005 Tissue factor pathway inhibitor (TFPI) is released following the administration of unfractionated heparin, low-molecular-weight heparins, defibrotide and PI-88. Heparin 98-105 tissue factor pathway inhibitor Homo sapiens 0-31 15678271-1 2005 Tissue factor pathway inhibitor (TFPI) is released following the administration of unfractionated heparin, low-molecular-weight heparins, defibrotide and PI-88. Heparin 98-105 tissue factor pathway inhibitor Homo sapiens 33-37 15678271-1 2005 Tissue factor pathway inhibitor (TFPI) is released following the administration of unfractionated heparin, low-molecular-weight heparins, defibrotide and PI-88. Heparin 128-136 tissue factor pathway inhibitor Homo sapiens 0-31 15678271-1 2005 Tissue factor pathway inhibitor (TFPI) is released following the administration of unfractionated heparin, low-molecular-weight heparins, defibrotide and PI-88. Heparin 128-136 tissue factor pathway inhibitor Homo sapiens 33-37 15678271-4 2005 Following the administration of 1 mg/kg of heparin, gammaparin, and C3, the functional levels of TFPI at 5 minutes were 2.40, 2.56, and 1.08 U/mL and the corresponding TFPI immunologic levels were 4.3-, 4.0-, and 2.1-fold, increased, respectively, over the baseline value. Heparin 43-50 tissue factor pathway inhibitor Homo sapiens 97-101 15678271-4 2005 Following the administration of 1 mg/kg of heparin, gammaparin, and C3, the functional levels of TFPI at 5 minutes were 2.40, 2.56, and 1.08 U/mL and the corresponding TFPI immunologic levels were 4.3-, 4.0-, and 2.1-fold, increased, respectively, over the baseline value. Heparin 43-50 tissue factor pathway inhibitor Homo sapiens 168-172 15678271-5 2005 From these results, it can be concluded that heparin and gammaparin produced similar levels of TFPI release. Heparin 45-52 tissue factor pathway inhibitor Homo sapiens 95-99 15570242-6 2004 Similar dose-dependent mobilization of TFPI and lipoprotein lipase (LPL), another glucosaminoglycan (GAG)-anchored protein of the endothelial membrane, was observed after both subcutaneous and intravenous administration of heparins. Heparin 223-231 tissue factor pathway inhibitor Homo sapiens 39-43 15815881-4 2004 Compared to control, increases in TFPI were seen with both unfractionated heparin (182% higher, p < 0.001) and enoxaparin (194% higher, p < 0.001). Heparin 74-81 tissue factor pathway inhibitor Homo sapiens 34-38 15570242-2 2004 Heparin treatment mobilizes TFPI into the circulation and contributes to the anticoagulant effects of heparins. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 28-32 15570242-7 2004 However, UFH induced a more efficient release of both TFPI and LPL into plasma than did LMWH at equivalent anti-Xa levels, indicating molecular-weight dependence of the release reactions. Heparin 9-12 tissue factor pathway inhibitor Homo sapiens 54-58 15570242-3 2004 Previous studies have demonstrated a selective depletion of intravascular TFPI by unfractionated heparin (UFH) but not by low-molecular-weight heparin (LMWH). Heparin 97-104 tissue factor pathway inhibitor Homo sapiens 74-78 15570242-10 2004 UFH and LMWH treatment reduced renal clearance of TFPI compared with the control regimen. Heparin 0-3 tissue factor pathway inhibitor Homo sapiens 50-54 15570242-3 2004 Previous studies have demonstrated a selective depletion of intravascular TFPI by unfractionated heparin (UFH) but not by low-molecular-weight heparin (LMWH). Heparin 106-109 tissue factor pathway inhibitor Homo sapiens 74-78 15570242-4 2004 In this study we sought to investigate the time- and dose-dependent relationships between release of TFPI and lipoprotein lipase (LPL) in respons to UFH and LMWH and to investigate whether the selective depletion of TFPI by UFH but not by LMWH is related to differential urinary excretion of TFPI. Heparin 149-152 tissue factor pathway inhibitor Homo sapiens 101-105 15570242-11 2004 Our findings suggest that displacement of TFPI from the endothelial-surface GAG is the main mechanism for TFPI release during heparin treatment in vivo and that differential urinary excretion of TFPI is not the explanation for selective depletion of TFPI during UFH treatment. Heparin 126-133 tissue factor pathway inhibitor Homo sapiens 42-46 12856386-1 2003 Low molecular weight heparins (LMWHs) stimulate the release of endothelial tissue factor pathway inhibitor (TFPI). Heparin 21-29 tissue factor pathway inhibitor Homo sapiens 75-106 15351861-0 2004 Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Heparin 74-81 tissue factor pathway inhibitor Homo sapiens 110-141 14675115-0 2003 Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 19-23 12856386-1 2003 Low molecular weight heparins (LMWHs) stimulate the release of endothelial tissue factor pathway inhibitor (TFPI). Heparin 21-29 tissue factor pathway inhibitor Homo sapiens 108-112 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 12-19 tissue factor pathway inhibitor Homo sapiens 90-121 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 12-19 tissue factor pathway inhibitor Homo sapiens 123-127 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 12-19 tissue factor pathway inhibitor Homo sapiens 219-223 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 183-190 tissue factor pathway inhibitor Homo sapiens 90-121 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 183-190 tissue factor pathway inhibitor Homo sapiens 123-127 12808176-1 2003 BACKGROUND: Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI), from the endothelium, but repeated administration of heparin depletes vascular stores of TFPI. Heparin 183-190 tissue factor pathway inhibitor Homo sapiens 219-223 12808176-8 2003 In patients switched to UFH, TF levels remained unchanged compared with pre-randomization values, TFPI increased at each interval of HD sessions (all P<0.035) and PF 1+2 increased pre-dialysis (P=0.015). Heparin 24-27 tissue factor pathway inhibitor Homo sapiens 98-102 12808176-10 2003 In contrast, baseline TFPI and its 10-min rise correlated inversely with the UFH loading dose (both P<0.040). Heparin 77-80 tissue factor pathway inhibitor Homo sapiens 22-26 12808176-12 2003 CONCLUSIONS: Depletion of heparin-releasable stores of TFPI is an untoward effect of repeated anticoagulation during maintenance HD therapy. Heparin 26-33 tissue factor pathway inhibitor Homo sapiens 55-59 12808176-13 2003 The traditional UFH regimen is more prothrombotic than single enoxaparin injections, with high loading doses of UFH being involved in TFPI exhaustion and subsequent hypercoagulability. Heparin 112-115 tissue factor pathway inhibitor Homo sapiens 134-138 12801846-1 2003 BACKGROUND AND OBJECTIVES: Unfractionated heparin and low molecular weight heparins exert their anticoagulant effect by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 42-49 tissue factor pathway inhibitor Homo sapiens 131-162 12801846-1 2003 BACKGROUND AND OBJECTIVES: Unfractionated heparin and low molecular weight heparins exert their anticoagulant effect by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 42-49 tissue factor pathway inhibitor Homo sapiens 164-168 12801846-1 2003 BACKGROUND AND OBJECTIVES: Unfractionated heparin and low molecular weight heparins exert their anticoagulant effect by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 75-83 tissue factor pathway inhibitor Homo sapiens 131-162 12801846-1 2003 BACKGROUND AND OBJECTIVES: Unfractionated heparin and low molecular weight heparins exert their anticoagulant effect by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. Heparin 75-83 tissue factor pathway inhibitor Homo sapiens 164-168 12801846-8 2003 With long periods of incubation (24-48h), both unfractionated heparin and enoxaparin significantly increased TFPI release (control vs. unfractionated heparin, p<0.05-0.001; control vs. enoxaparin, p<0.01-0.001) and also reduced the release of vWF in the culture medium, though no variations in endothelial cell procoagulant activity or TF content were observed. Heparin 62-69 tissue factor pathway inhibitor Homo sapiens 109-113 12624625-2 2003 Heparin caused a dose-dependent increase in plasma TFPI concentrations in both arms (ANOVA, p <0.0001). Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 51-55 12893029-13 2003 The concentration of TFPI was significantly increased following incubation with thrombin and heparin in a dose- and time-dependent manner, although the amount of TFPI mRNA was not changed. Heparin 93-100 tissue factor pathway inhibitor Homo sapiens 21-25 12893029-15 2003 Thrombin and heparin stimulated TFPI secretion from PTEC. Heparin 13-20 tissue factor pathway inhibitor Homo sapiens 32-36 12893029-17 2003 The augmentation of TFPI secretion by heparin may play an important role in the modulation of anticoagulant properties of PTEC. Heparin 38-45 tissue factor pathway inhibitor Homo sapiens 20-24 12624625-3 2003 Estimated net forearm TFPI release was 7 +/- 16, 29 +/- 20 and 138 +/- 72 ng/100 mL tissue/min during 10, 30 and 100 IU/min of heparin respectively (ANOVA, p <0.0001). Heparin 127-134 tissue factor pathway inhibitor Homo sapiens 22-26 12624625-4 2003 Compared to the systemic circulation, the forearm sensitivity to heparin induced TFPI release was 3.6-fold lower (166 +/- 67 ng/IU vs. 596 +/- 252 ng/IU: t-test, p = 0.004). Heparin 65-72 tissue factor pathway inhibitor Homo sapiens 81-85 12482841-6 2002 Pretreatment of the placental fragments with PIPLC increases the amount of heparin-releasable TFPI by approximately 3-fold. Heparin 75-82 tissue factor pathway inhibitor Homo sapiens 94-98 14574072-0 2003 Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor. Heparin 58-65 tissue factor pathway inhibitor Homo sapiens 77-108 14574072-3 2003 METHODS/RESULTS: Human umbilical vein endothelial cells (HUVEC) were incubated with unfractionated heparin (1.5 U/ml) (to provoke tissue factor pathway inhibitor [TFPI] release) followed by the addition of varying concentrations of alteplase (recombinant tissue plasminogen activator), plasminogen, their combination or plasmin alone. Heparin 99-106 tissue factor pathway inhibitor Homo sapiens 130-161 12519315-0 2003 Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria. Heparin 53-60 tissue factor pathway inhibitor Homo sapiens 0-31 12519315-0 2003 Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria. Heparin 53-60 tissue factor pathway inhibitor Homo sapiens 33-37 12519315-1 2003 AIMS: To study heparin-stimulated TFPI release in relation to complications in Type 1 diabetic patients. Heparin 15-22 tissue factor pathway inhibitor Homo sapiens 34-38 12519315-8 2003 At all time points after heparin administration, TFPI activity in group III was significantly higher than in group I. Heparin 25-32 tissue factor pathway inhibitor Homo sapiens 49-53 12519315-9 2003 TFPI activity was also higher in group III than in group II 5-30 min post-heparin. Heparin 74-81 tissue factor pathway inhibitor Homo sapiens 0-4 12519315-13 2003 The increase in heparin-stimulated TFPI release in patients with albuminuria is higher than in patients with retinopathy or without complications. Heparin 16-23 tissue factor pathway inhibitor Homo sapiens 35-39 12482841-9 2002 Heparin-releasable TFPI likely represents only a small portion of the total TFPI on endothelium that remains attached to cell-surface glycosaminoglycans after cleavage of the GPI anchor by endogenous enzymes. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 19-23 12482841-9 2002 Heparin-releasable TFPI likely represents only a small portion of the total TFPI on endothelium that remains attached to cell-surface glycosaminoglycans after cleavage of the GPI anchor by endogenous enzymes. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 76-80 11854880-0 2002 Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. Heparin 78-85 tissue factor pathway inhibitor Homo sapiens 0-31 12714831-0 2002 Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. Heparin 38-45 tissue factor pathway inhibitor Homo sapiens 108-139 12714831-0 2002 Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. Heparin 71-78 tissue factor pathway inhibitor Homo sapiens 108-139 12714831-1 2002 OBJECTIVES: The purpose of our study was to characterize tissue factor pathway inhibitor (TFPI) release from human vascular endothelial cells following daily exposure to varying concentrations of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 211-218 tissue factor pathway inhibitor Homo sapiens 57-88 12714831-1 2002 OBJECTIVES: The purpose of our study was to characterize tissue factor pathway inhibitor (TFPI) release from human vascular endothelial cells following daily exposure to varying concentrations of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 211-218 tissue factor pathway inhibitor Homo sapiens 90-94 12714831-1 2002 OBJECTIVES: The purpose of our study was to characterize tissue factor pathway inhibitor (TFPI) release from human vascular endothelial cells following daily exposure to varying concentrations of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 220-223 tissue factor pathway inhibitor Homo sapiens 57-88 12714831-1 2002 OBJECTIVES: The purpose of our study was to characterize tissue factor pathway inhibitor (TFPI) release from human vascular endothelial cells following daily exposure to varying concentrations of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 250-257 tissue factor pathway inhibitor Homo sapiens 57-88 12714831-1 2002 OBJECTIVES: The purpose of our study was to characterize tissue factor pathway inhibitor (TFPI) release from human vascular endothelial cells following daily exposure to varying concentrations of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 250-257 tissue factor pathway inhibitor Homo sapiens 90-94 12714831-12 2002 The differing effects of UFH and LMWH on vascular endothelial cell TFPI synthesis, release and reserve with prolonged administration require further investigation. Heparin 25-28 tissue factor pathway inhibitor Homo sapiens 67-71 12021535-0 2002 Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients. Heparin 65-72 tissue factor pathway inhibitor Homo sapiens 83-114 12492611-0 2002 Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Heparin 18-25 tissue factor pathway inhibitor Homo sapiens 34-38 12492611-0 2002 Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Heparin 73-80 tissue factor pathway inhibitor Homo sapiens 34-38 12492611-1 2002 AIMS: Heparin releases tissue factor pathway inhibitor (TFPI) from the endothelium and this release may decrease after repeated high dose heparin administration. Heparin 138-145 tissue factor pathway inhibitor Homo sapiens 23-54 12492611-1 2002 AIMS: Heparin releases tissue factor pathway inhibitor (TFPI) from the endothelium and this release may decrease after repeated high dose heparin administration. Heparin 138-145 tissue factor pathway inhibitor Homo sapiens 56-60 12492611-8 2002 The relationship between heparin concentration (anti-IIa activity) and TFPI concentration followed a maximum effect model and a clockwise loop (proteresis) was observed. Heparin 25-32 tissue factor pathway inhibitor Homo sapiens 71-75 12492611-9 2002 The TFPI release rate rapidly increased to maximum of 200 +/- 45 micro g min-1 after 17.5 min heparin infusion but did not increase further although heparin concentrations further doubled. Heparin 94-101 tissue factor pathway inhibitor Homo sapiens 4-8 12492611-11 2002 CONCLUSIONS: Our application of concentration-effect models and pharmacokinetic principles to these haemostatic variables showed that endothelial TFPI release has a maximum that is already reached at low heparin dose, corresponding with an anti-IIa activity of 0.08 IU ml-1. Heparin 204-211 tissue factor pathway inhibitor Homo sapiens 146-150 12492611-13 2002 These findings may be of importance for the heparin dose used in conditions such as unstable angina, in which the favourable effects of heparin have been ascribed to its ability to release TFPI. Heparin 44-51 tissue factor pathway inhibitor Homo sapiens 189-193 12492611-13 2002 These findings may be of importance for the heparin dose used in conditions such as unstable angina, in which the favourable effects of heparin have been ascribed to its ability to release TFPI. Heparin 136-143 tissue factor pathway inhibitor Homo sapiens 189-193 12063117-0 2002 Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI). Heparin 10-17 tissue factor pathway inhibitor Homo sapiens 55-86 12063117-0 2002 Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI). Heparin 10-17 tissue factor pathway inhibitor Homo sapiens 88-92 12063117-2 2002 In order to elucidate the minimal size of heparin chain required for the interaction with TFPI, we prepared a series of heparin-derived oligosaccharides with tailored chain length ranged from disaccharide to eicosasaccharide after the successive treatments of heparin, including partial N-desulphation, deaminative cleavage with nitrous acid and gel-filtration. Heparin 42-49 tissue factor pathway inhibitor Homo sapiens 90-94 12063117-2 2002 In order to elucidate the minimal size of heparin chain required for the interaction with TFPI, we prepared a series of heparin-derived oligosaccharides with tailored chain length ranged from disaccharide to eicosasaccharide after the successive treatments of heparin, including partial N-desulphation, deaminative cleavage with nitrous acid and gel-filtration. Heparin 120-127 tissue factor pathway inhibitor Homo sapiens 90-94 12028043-0 2002 Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. Heparin 124-131 tissue factor pathway inhibitor Homo sapiens 18-49 11854880-1 2002 OBJECTIVE: To identify patients with poor tissue factor pathway inhibitor (TFPI) response to heparin and observe any association with increased risk of excessive coagulation activation, morbidity, or mortality. Heparin 93-100 tissue factor pathway inhibitor Homo sapiens 42-73 11854880-1 2002 OBJECTIVE: To identify patients with poor tissue factor pathway inhibitor (TFPI) response to heparin and observe any association with increased risk of excessive coagulation activation, morbidity, or mortality. Heparin 93-100 tissue factor pathway inhibitor Homo sapiens 75-79 11854880-12 2002 CONCLUSION: The TFPI response to heparin is heterogenous. Heparin 33-40 tissue factor pathway inhibitor Homo sapiens 16-20 11804978-2 2002 In addition, TFPI-1 is released from microvascular endothelial cells after treatment with heparin and thereby contributes to its antithrombotic properties. Heparin 90-97 tissue factor pathway inhibitor Homo sapiens 13-19 11772005-0 2002 Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Heparin 25-32 tissue factor pathway inhibitor Homo sapiens 77-108 11772005-1 2002 Tissue factor pathway inhibitor (TFPI) inhibits the activity of coagulation factor VIIa and Xa through its K1 and K2 domain, respectively, and the inhibitory activity is enhanced by heparin. Heparin 182-189 tissue factor pathway inhibitor Homo sapiens 0-31 11772005-1 2002 Tissue factor pathway inhibitor (TFPI) inhibits the activity of coagulation factor VIIa and Xa through its K1 and K2 domain, respectively, and the inhibitory activity is enhanced by heparin. Heparin 182-189 tissue factor pathway inhibitor Homo sapiens 33-37 11772005-10 2002 It is likely that heparin simply increases the local concentration of TFPI on the cell surface and stabilizes the initial complex that forms. Heparin 18-25 tissue factor pathway inhibitor Homo sapiens 70-74 11709459-2 2001 Although most TFPI is found in association with plasma lipoproteins and platelets, the functional pool is bound to vascular endothelium and is released into the circulation on stimulation with heparin or low molecular weight heparin (LMWH). Heparin 193-200 tissue factor pathway inhibitor Homo sapiens 14-18 11848461-3 2002 In the present study, it was found, by means of agarose gel electrophoresis, that the pre-incubation of full-length rTFPI with heparin or the carboxy (C)-terminal part (peptide 240-265) of TFPI prevented the association with ox-LDL in a dose-dependent manner. Heparin 127-134 tissue factor pathway inhibitor Homo sapiens 117-121 11709459-2 2001 Although most TFPI is found in association with plasma lipoproteins and platelets, the functional pool is bound to vascular endothelium and is released into the circulation on stimulation with heparin or low molecular weight heparin (LMWH). Heparin 225-232 tissue factor pathway inhibitor Homo sapiens 14-18 11776326-1 2001 We investigated the localisation, gene expression, and activity of tissue factor pathway inhibitor (TFPI) in endothelial cells (EC) grown in static conditions or under shear stress, in the presence of unfractionated heparin (UFH) and two low-molecular-weight heparins (LMWHs). Heparin 225-228 tissue factor pathway inhibitor Homo sapiens 100-104 11776326-4 2001 In EC grown under shear stress (0.27, 4.1 and 19 dyne/cm2) and incubated with each heparin for 24 h, the release of TFPI was significantly correlated with the level of flow for bemiparin and dalteparin, but not for UFH. Heparin 83-90 tissue factor pathway inhibitor Homo sapiens 116-120 11776326-4 2001 In EC grown under shear stress (0.27, 4.1 and 19 dyne/cm2) and incubated with each heparin for 24 h, the release of TFPI was significantly correlated with the level of flow for bemiparin and dalteparin, but not for UFH. Heparin 215-218 tissue factor pathway inhibitor Homo sapiens 116-120 11776326-6 2001 The expression of TFPI mRNA, determined by Northern blotting, was specifically modulated by heparins. Heparin 92-100 tissue factor pathway inhibitor Homo sapiens 18-22 11668420-0 2001 Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Heparin 40-47 tissue factor pathway inhibitor Homo sapiens 63-94 11772296-9 2001 TFPI can be administered exogenously in high doses to suppress TF-mediated effects, alternatively high amounts of TFPI can be released from intravascular stores by other drugs, such as heparin and low molecular weight heparins (LMWH). Heparin 185-192 tissue factor pathway inhibitor Homo sapiens 114-118 11772296-9 2001 TFPI can be administered exogenously in high doses to suppress TF-mediated effects, alternatively high amounts of TFPI can be released from intravascular stores by other drugs, such as heparin and low molecular weight heparins (LMWH). Heparin 218-226 tissue factor pathway inhibitor Homo sapiens 0-4 11772296-9 2001 TFPI can be administered exogenously in high doses to suppress TF-mediated effects, alternatively high amounts of TFPI can be released from intravascular stores by other drugs, such as heparin and low molecular weight heparins (LMWH). Heparin 218-226 tissue factor pathway inhibitor Homo sapiens 114-118 11668420-1 2001 The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. Heparin 80-88 tissue factor pathway inhibitor Homo sapiens 28-59 11668420-1 2001 The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. Heparin 80-88 tissue factor pathway inhibitor Homo sapiens 61-65 11668420-2 2001 In a clinical study in healthy volunteers, we recently found that the specific potency of a heparin to mobilize TFPI from the vessel wall increases with its molecular weight (MW). Heparin 92-99 tissue factor pathway inhibitor Homo sapiens 112-116 11668420-4 2001 A further question is whether the MW of heparin influences not only the release of TFPI but also its potential association with lipoproteins. Heparin 40-47 tissue factor pathway inhibitor Homo sapiens 83-87 11668420-6 2001 Only the TFPI released by unfractionated heparin (UFH) circulated completely as free TFPI. Heparin 41-48 tissue factor pathway inhibitor Homo sapiens 9-13 11668420-6 2001 Only the TFPI released by unfractionated heparin (UFH) circulated completely as free TFPI. Heparin 50-53 tissue factor pathway inhibitor Homo sapiens 9-13 11668420-7 2001 With decreasing heparin MW, the percentage of released free TFPI on released total TFPI decreased to 57%. Heparin 16-23 tissue factor pathway inhibitor Homo sapiens 60-64 11668420-7 2001 With decreasing heparin MW, the percentage of released free TFPI on released total TFPI decreased to 57%. Heparin 16-23 tissue factor pathway inhibitor Homo sapiens 83-87 11668420-8 2001 As a consequence, the longer the heparin chains are, the better they are at preventing the binding of the released, originally free, TFPI to plasma lipoproteins. Heparin 33-40 tissue factor pathway inhibitor Homo sapiens 133-137 11668420-9 2001 Because only free TFPI is known to exhibit anticoagulant activity, the activity of released TFPI is better the higher the MW of the applied heparin is. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 18-22 11668420-9 2001 Because only free TFPI is known to exhibit anticoagulant activity, the activity of released TFPI is better the higher the MW of the applied heparin is. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 92-96 11668420-10 2001 In conclusion, in addition to the potency of heparin to mobilize TFPI, there is its influence on the circulating form, and thus the anticoagulant activity of the released TFPI depends on its MW. Heparin 45-52 tissue factor pathway inhibitor Homo sapiens 65-69 11668420-10 2001 In conclusion, in addition to the potency of heparin to mobilize TFPI, there is its influence on the circulating form, and thus the anticoagulant activity of the released TFPI depends on its MW. Heparin 45-52 tissue factor pathway inhibitor Homo sapiens 171-175 10928482-9 2000 Functional factor VIIa activity fell significantly in the systemic circulation, probably due to the heparin-induced increase (approximately 15-fold) in tissue factor pathway inhibitor (TFPI), but was elevated in pericardial blood compared with that taken from the central line catheter (p <0.006). Heparin 100-107 tissue factor pathway inhibitor Homo sapiens 152-183 11441984-0 2001 Tissue factor pathway inhibitor release induced by defibrotide and heparins. Heparin 67-75 tissue factor pathway inhibitor Homo sapiens 0-31 11441984-4 2001 UFH caused a 4-fold increase in plasma TFPI at 5 minutes, with a decrease that was parallel to the heparin level measured by the anti-Xa assay. Heparin 0-3 tissue factor pathway inhibitor Homo sapiens 39-43 11441984-12 2001 Furthermore, the release of TFPI by heparin is mediated by non-antithrombin III binding fragments. Heparin 36-43 tissue factor pathway inhibitor Homo sapiens 28-32 11434705-0 2001 The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Heparin 54-61 tissue factor pathway inhibitor Homo sapiens 65-96 11434705-2 2001 Recent work has suggested that tissue factor pathway inhibitor (TFPI) may contribute to the antithrombotic activity of heparin by inhibiting the extrinsic pathway of coagulation. Heparin 119-126 tissue factor pathway inhibitor Homo sapiens 31-62 11434705-2 2001 Recent work has suggested that tissue factor pathway inhibitor (TFPI) may contribute to the antithrombotic activity of heparin by inhibiting the extrinsic pathway of coagulation. Heparin 119-126 tissue factor pathway inhibitor Homo sapiens 64-68 11434705-3 2001 We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. Heparin 35-42 tissue factor pathway inhibitor Homo sapiens 46-50 11434705-3 2001 We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. Heparin 35-42 tissue factor pathway inhibitor Homo sapiens 171-175 11434705-3 2001 We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. Heparin 91-98 tissue factor pathway inhibitor Homo sapiens 46-50 11434705-3 2001 We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. Heparin 91-98 tissue factor pathway inhibitor Homo sapiens 171-175 11434705-3 2001 We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. Heparin 91-98 tissue factor pathway inhibitor Homo sapiens 46-50 11434705-3 2001 We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. Heparin 91-98 tissue factor pathway inhibitor Homo sapiens 171-175 11434705-4 2001 In contrast, therapeutic doses of the low molecular weight heparin, dalteparin, resulted in significantly less TFPI induction. Heparin 59-66 tissue factor pathway inhibitor Homo sapiens 111-115 11380428-2 2001 The major part of TFPI is releasable by heparin. Heparin 40-47 tissue factor pathway inhibitor Homo sapiens 18-22 11380428-3 2001 We recently found eight patients with thrombosis and low levels of heparin-releasable TFPI in whom we investigated the TFPI gene for mutations. Heparin 67-74 tissue factor pathway inhibitor Homo sapiens 86-90 11380428-3 2001 We recently found eight patients with thrombosis and low levels of heparin-releasable TFPI in whom we investigated the TFPI gene for mutations. Heparin 67-74 tissue factor pathway inhibitor Homo sapiens 119-123 11254842-9 2001 Heparin concentration correlated with levels of total TFPI (r2 = 0.613, p < 0.0001) and free TFPI (r2 = 0.689, p < 0.0001). Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 54-58 11254842-9 2001 Heparin concentration correlated with levels of total TFPI (r2 = 0.613, p < 0.0001) and free TFPI (r2 = 0.689, p < 0.0001). Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 96-100 11254842-11 2001 CONCLUSION: These data indicate that TFPI release by heparin probably has an important role in the suppression of the tissue factor-dependent coagulation pathway during CPB. Heparin 53-60 tissue factor pathway inhibitor Homo sapiens 37-41 11229821-2 2001 Free TFPI is the most potent and important type, because it is released from endothelial cells following an injection of heparin, or as a result of pathological stimuli. Heparin 121-128 tissue factor pathway inhibitor Homo sapiens 5-9 11132652-5 2000 Additionally, we conducted in vitro experiments to investigate the effect of unfractionated heparin and TFPI, which is released from the endothelium by heparin, on FVII:C, FVIIa, and FVII:Ag. Heparin 152-159 tissue factor pathway inhibitor Homo sapiens 104-108 11132652-6 2000 Heparin infusion decreased triglycerides and increased FFA and TFPI. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 63-67 11150580-2 2000 Heparin is known to exert its antithrombotic effects by accelerating the effect of antithrombin (AT) and by mobilizing tissue factor pathway inhibitor (TFPI) into the circulation from vascular endothelium. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 119-150 11150580-2 2000 Heparin is known to exert its antithrombotic effects by accelerating the effect of antithrombin (AT) and by mobilizing tissue factor pathway inhibitor (TFPI) into the circulation from vascular endothelium. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 152-156 11150580-10 2000 The present study shows that the FVIIa assay is sensitive to TFPI and AT, especially during heparin treatment, and thereby indicates that the heparin-induced decrease in FVIIa is affected by interactions between TFPI and AT with the FVIIa assay. Heparin 92-99 tissue factor pathway inhibitor Homo sapiens 61-65 11150580-10 2000 The present study shows that the FVIIa assay is sensitive to TFPI and AT, especially during heparin treatment, and thereby indicates that the heparin-induced decrease in FVIIa is affected by interactions between TFPI and AT with the FVIIa assay. Heparin 142-149 tissue factor pathway inhibitor Homo sapiens 61-65 11150580-10 2000 The present study shows that the FVIIa assay is sensitive to TFPI and AT, especially during heparin treatment, and thereby indicates that the heparin-induced decrease in FVIIa is affected by interactions between TFPI and AT with the FVIIa assay. Heparin 142-149 tissue factor pathway inhibitor Homo sapiens 212-216 10922378-8 2000 Binding experiments done in the presence of heparin and with altered forms of TFPI suggest that the basic C-terminal region of TFPI is required for TSP-1 binding. Heparin 44-51 tissue factor pathway inhibitor Homo sapiens 127-131 11457474-1 2001 Several studies have shown that tissue factor pathway inhibitor (TFPI) is released after the intravenous and subcutaneous administration of heparin and heparin-related drugs. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 32-63 11457474-1 2001 Several studies have shown that tissue factor pathway inhibitor (TFPI) is released after the intravenous and subcutaneous administration of heparin and heparin-related drugs. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 65-69 11457474-1 2001 Several studies have shown that tissue factor pathway inhibitor (TFPI) is released after the intravenous and subcutaneous administration of heparin and heparin-related drugs. Heparin 152-159 tissue factor pathway inhibitor Homo sapiens 32-63 11457474-1 2001 Several studies have shown that tissue factor pathway inhibitor (TFPI) is released after the intravenous and subcutaneous administration of heparin and heparin-related drugs. Heparin 152-159 tissue factor pathway inhibitor Homo sapiens 65-69 10928482-9 2000 Functional factor VIIa activity fell significantly in the systemic circulation, probably due to the heparin-induced increase (approximately 15-fold) in tissue factor pathway inhibitor (TFPI), but was elevated in pericardial blood compared with that taken from the central line catheter (p <0.006). Heparin 100-107 tissue factor pathway inhibitor Homo sapiens 185-189 11251341-4 2000 TFPI is released from the vascular endothelium after injection of either unfractionated heparin (UFH) or low-molecular-weight heparins (LMWHs), which may then provide high concentrations of TFPI at sites of tissue damage and ongoing thrombosis. Heparin 88-95 tissue factor pathway inhibitor Homo sapiens 0-4 10847421-0 2000 Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Heparin 103-111 tissue factor pathway inhibitor Homo sapiens 37-68 10847421-1 2000 Tissue factor pathway inhibitor (TFPI) is released to circulating blood after intravenous and subcutaneous injections of heparins, and may thus contribute to the antithrombotic effect of heparins. Heparin 121-129 tissue factor pathway inhibitor Homo sapiens 0-31 10847421-1 2000 Tissue factor pathway inhibitor (TFPI) is released to circulating blood after intravenous and subcutaneous injections of heparins, and may thus contribute to the antithrombotic effect of heparins. Heparin 121-129 tissue factor pathway inhibitor Homo sapiens 33-37 10847421-1 2000 Tissue factor pathway inhibitor (TFPI) is released to circulating blood after intravenous and subcutaneous injections of heparins, and may thus contribute to the antithrombotic effect of heparins. Heparin 187-195 tissue factor pathway inhibitor Homo sapiens 0-31 10847421-1 2000 Tissue factor pathway inhibitor (TFPI) is released to circulating blood after intravenous and subcutaneous injections of heparins, and may thus contribute to the antithrombotic effect of heparins. Heparin 187-195 tissue factor pathway inhibitor Homo sapiens 33-37 10847421-2 2000 A previous study suggested different abilities of various low molecular weight heparins (LMWH) to release endogenous TFPI, but the dose-response relationship was not determined. Heparin 79-87 tissue factor pathway inhibitor Homo sapiens 117-121 10896252-3 2000 and administration of unfractionated heparin (UFH) in vivo causes a prompt mobilization of TFPI into the circulation. Heparin 37-44 tissue factor pathway inhibitor Homo sapiens 91-95 10896252-3 2000 and administration of unfractionated heparin (UFH) in vivo causes a prompt mobilization of TFPI into the circulation. Heparin 46-49 tissue factor pathway inhibitor Homo sapiens 91-95 10896252-4 2000 The present study was conducted to investigate how UFH affected the synthesis, secretion and anticoagulant potency of TFPI in endothelial cells in vitro. Heparin 51-54 tissue factor pathway inhibitor Homo sapiens 118-122 10896252-6 2000 Stimulation of ECV304 cells with UFH caused a prompt dose-dependent (0-5 IU UFH/ml) release of TFPI to the medium accompanied by no change of TFPI at the surface membrane assessed by immunocytochemical methods. Heparin 33-36 tissue factor pathway inhibitor Homo sapiens 95-99 10896252-8 2000 Stimulation of ECV304 cells for 24 hrs with various concentrations of UFH caused a dose-dependent increase of TFPI in the medium (6.2-29.6 ng/10(6) cells within the concentration range 0-10 IU/ml). Heparin 70-73 tissue factor pathway inhibitor Homo sapiens 110-114 10896252-10 2000 Long-term incubation of ECV304 cells with 5.0 IU/ml UFH caused a 5-10 fold increase in the TFPI concentration accumulated in the medium over 48 hrs. Heparin 52-55 tissue factor pathway inhibitor Homo sapiens 91-95 10896252-12 2000 The procoagulant activity of the cells was downregulated by 36% and the contribution of TFPI to the anticoagulant potency of ECV304 cells was moderately increased after 24 hrs heparin stimulation. Heparin 176-183 tissue factor pathway inhibitor Homo sapiens 88-92 11251341-4 2000 TFPI is released from the vascular endothelium after injection of either unfractionated heparin (UFH) or low-molecular-weight heparins (LMWHs), which may then provide high concentrations of TFPI at sites of tissue damage and ongoing thrombosis. Heparin 97-100 tissue factor pathway inhibitor Homo sapiens 0-4 11251341-4 2000 TFPI is released from the vascular endothelium after injection of either unfractionated heparin (UFH) or low-molecular-weight heparins (LMWHs), which may then provide high concentrations of TFPI at sites of tissue damage and ongoing thrombosis. Heparin 97-100 tissue factor pathway inhibitor Homo sapiens 190-194 11251341-4 2000 TFPI is released from the vascular endothelium after injection of either unfractionated heparin (UFH) or low-molecular-weight heparins (LMWHs), which may then provide high concentrations of TFPI at sites of tissue damage and ongoing thrombosis. Heparin 126-134 tissue factor pathway inhibitor Homo sapiens 0-4 11251341-4 2000 TFPI is released from the vascular endothelium after injection of either unfractionated heparin (UFH) or low-molecular-weight heparins (LMWHs), which may then provide high concentrations of TFPI at sites of tissue damage and ongoing thrombosis. Heparin 126-134 tissue factor pathway inhibitor Homo sapiens 190-194 11251341-5 2000 In dilute prothrombin-time-based assays, released TFPI contributes approximately one-third to the anticoagulant effect of heparin, the remaining being accounted for by antithrombin. Heparin 122-129 tissue factor pathway inhibitor Homo sapiens 50-54 11251341-7 2000 UFH and LMWH exert differential effects on intravascular TFPI. Heparin 0-3 tissue factor pathway inhibitor Homo sapiens 57-61 11251341-8 2000 UFH, but not LMWH, given in therapeutic doses, is associated with a progressive depletion of TFPI, which is associated with a strong rebound activation of coagulation after cessation of treatment. Heparin 0-3 tissue factor pathway inhibitor Homo sapiens 93-97 10545520-5 1999 Immobilized heparin, a mimic for extracellular matrix-associated proteoglycans, binds physiological concentrations of TFPI-1 in a conformation that supports TF-VIIa-dependent cell adhesion. Heparin 12-19 tissue factor pathway inhibitor Homo sapiens 118-124 10664333-4 2000 We found that changes in the total plasma TFPI antigen level were significantly dependent on the level of free TFPI antigen (r = 0.96, P < 0.0001) which increased significantly after heparin injection (P < 0.0001), and increased further during the bypass period (P < 0.005). Heparin 186-193 tissue factor pathway inhibitor Homo sapiens 42-46 10664333-4 2000 We found that changes in the total plasma TFPI antigen level were significantly dependent on the level of free TFPI antigen (r = 0.96, P < 0.0001) which increased significantly after heparin injection (P < 0.0001), and increased further during the bypass period (P < 0.005). Heparin 186-193 tissue factor pathway inhibitor Homo sapiens 111-115 10664333-6 2000 When heparin was neutralized by protamine, the free TFPI antigen level decreased immediately, but remained higher than the preoperative level (P < 0.005). Heparin 5-12 tissue factor pathway inhibitor Homo sapiens 52-56 10606880-0 1999 Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Heparin 106-113 tissue factor pathway inhibitor Homo sapiens 21-52 10606880-11 1999 On UFH administered once daily, basal free TFPI antigen decreased by 50%, 56% and 27% on day 2, 3 and 5 respectively, compared with day 1. Heparin 3-6 tissue factor pathway inhibitor Homo sapiens 43-47 10613653-8 1999 Further, increased synthesis of TFPI initially led to the saturation of heparin-releasable binding sites. Heparin 72-79 tissue factor pathway inhibitor Homo sapiens 32-36 10613653-9 1999 TFPI-Ag was detected by Western blotting, 35S-metabolic labeling and activity assays on the conditioned media, heparin-released material from cells, and in cell lysates. Heparin 111-118 tissue factor pathway inhibitor Homo sapiens 0-4 10479670-3 1999 Here we describe the in vitro effects of heparin on the cellular localization, gene expression, and release of TFPI in human ECs in culture. Heparin 41-48 tissue factor pathway inhibitor Homo sapiens 111-115 10479670-0 1999 Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Heparin 20-27 tissue factor pathway inhibitor Homo sapiens 61-92 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 20-27 tissue factor pathway inhibitor Homo sapiens 144-148 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 20-27 tissue factor pathway inhibitor Homo sapiens 197-201 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 20-27 tissue factor pathway inhibitor Homo sapiens 197-201 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 29-32 tissue factor pathway inhibitor Homo sapiens 144-148 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 29-32 tissue factor pathway inhibitor Homo sapiens 197-201 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 29-32 tissue factor pathway inhibitor Homo sapiens 197-201 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 59-66 tissue factor pathway inhibitor Homo sapiens 144-148 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 59-66 tissue factor pathway inhibitor Homo sapiens 197-201 10479670-4 1999 Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Heparin 59-66 tissue factor pathway inhibitor Homo sapiens 197-201 10479670-10 1999 After the first 4 to 8 hours, depletion of intracellular TFPI was observed, more significantly with UFH. Heparin 100-103 tissue factor pathway inhibitor Homo sapiens 57-61 10479670-13 1999 Heparin-stimulated release of TFPI decreased significantly in the presence of PMA to a level that was 2. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 30-34 10479670-16 1999 Altogether, our results suggest that the heparin-induced release of TFPI might involve a more specific mechanism(s) than the previously hypothesized simple displacement of TFPI from the cell surface glycocalyx. Heparin 41-48 tissue factor pathway inhibitor Homo sapiens 68-72 10479670-16 1999 Altogether, our results suggest that the heparin-induced release of TFPI might involve a more specific mechanism(s) than the previously hypothesized simple displacement of TFPI from the cell surface glycocalyx. Heparin 41-48 tissue factor pathway inhibitor Homo sapiens 172-176 10479670-17 1999 We assume that the increased secretion and redistribution of cellular TFPI induced by heparins in ECs in culture can play an important role in the modulation of the anticoagulant properties of the endothelium. Heparin 86-94 tissue factor pathway inhibitor Homo sapiens 70-74 10494757-5 1999 Intravenous injection of 7500 IU unfractionated heparin induced a significant further increase of TFPI in two patients with high pre-heparin levels. Heparin 48-55 tissue factor pathway inhibitor Homo sapiens 98-102 10494757-5 1999 Intravenous injection of 7500 IU unfractionated heparin induced a significant further increase of TFPI in two patients with high pre-heparin levels. Heparin 133-140 tissue factor pathway inhibitor Homo sapiens 98-102 9974412-7 1999 The TFPI in HMDM supernatants possessed heparin-binding affinity, suggesting potential interaction of TFPI with heparan sulfate proteoglycans. Heparin 40-47 tissue factor pathway inhibitor Homo sapiens 4-8 10397725-11 1999 Cycloheximide, but not actinomycin-D, treatment inhibited the serum and bFGF/heparin-induced increase in TFPI activity in PASMC. Heparin 77-84 tissue factor pathway inhibitor Homo sapiens 105-109 10336236-3 1999 Blood samples were drawn before and 5 minutes after an intravenous injection of unfractionated heparin 5000 IE, which is known to cause TFPI release in healthy individuals. Heparin 95-102 tissue factor pathway inhibitor Homo sapiens 136-140 10336236-6 1999 The TFPI levels showed a considerable rise in both patients and controls after heparin injection. Heparin 79-86 tissue factor pathway inhibitor Homo sapiens 4-8 10336236-11 1999 In conclusion, we have found that patients with APA have higher TFPI amidolytic activity/antigen level both before and after heparin stimulation of TFPI release. Heparin 125-132 tissue factor pathway inhibitor Homo sapiens 148-152 10235445-0 1999 Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Heparin 74-81 tissue factor pathway inhibitor Homo sapiens 28-59 9974412-7 1999 The TFPI in HMDM supernatants possessed heparin-binding affinity, suggesting potential interaction of TFPI with heparan sulfate proteoglycans. Heparin 40-47 tissue factor pathway inhibitor Homo sapiens 102-106 10397725-8 1999 On Western blot analysis, a protein consistent with full-length TFPI (42 kD) was identified in the conditioned media of PASMC, and the levels of the protein were much higher in the conditioned media of serum and bFGF/heparin-treated cells. Heparin 217-224 tissue factor pathway inhibitor Homo sapiens 64-68 10065895-7 1999 We showed that plasma-free TFPI levels after administration of heparin, which may indicate endothelial cell associated TFPI levels, increased in patients with angina pectoris compared with patients with chest pain syndrome. Heparin 63-70 tissue factor pathway inhibitor Homo sapiens 27-31 10063992-0 1999 Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Heparin 14-21 tissue factor pathway inhibitor Homo sapiens 33-64 10063992-3 1999 To investigate if deficiency of heparin-releasable TFPI is associated with thrombosis. Heparin 32-39 tissue factor pathway inhibitor Homo sapiens 51-55 10063992-4 1999 we measured TFPI activity in plasma before and 10 min after intravenous injection of 7500 IU unfractionated heparin in 64 young patients with venous thrombosis, 49 young patients with arterial thrombosis and 38 healthy individuals. Heparin 108-115 tissue factor pathway inhibitor Homo sapiens 12-16 10063992-8 1999 However, the causative role of low heparin-releasable TFPI remains uncertain, because co-segregation of the defect with thrombotic symptoms could not be demonstrated in the small number of families studied. Heparin 35-42 tissue factor pathway inhibitor Homo sapiens 54-58 11938732-3 1999 The results were that TFPI and ACT were significantly increased after heparin injection and during CPB. Heparin 70-77 tissue factor pathway inhibitor Homo sapiens 22-26 11938732-4 1999 The changes of TFPI and ACT were similar and pathophysiological; it was evident that heparin stimulated TFPI release and ACT prolonged during cardiac operation with CPB. Heparin 85-92 tissue factor pathway inhibitor Homo sapiens 15-19 11938732-4 1999 The changes of TFPI and ACT were similar and pathophysiological; it was evident that heparin stimulated TFPI release and ACT prolonged during cardiac operation with CPB. Heparin 85-92 tissue factor pathway inhibitor Homo sapiens 104-108 10065895-7 1999 We showed that plasma-free TFPI levels after administration of heparin, which may indicate endothelial cell associated TFPI levels, increased in patients with angina pectoris compared with patients with chest pain syndrome. Heparin 63-70 tissue factor pathway inhibitor Homo sapiens 119-123 9778325-7 1998 For the entire group, 30000 IU SNAC and heparin elevated TFPI from 74.9+/-7.6 to 254.2+/-12.3 mg/mL (P<0.001) 1 hour after dosing (P<0.001). Heparin 40-47 tissue factor pathway inhibitor Homo sapiens 57-61 9798992-0 1998 Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Heparin 13-20 tissue factor pathway inhibitor Homo sapiens 30-61 9798992-2 1998 Tissue factor pathway inhibitor (TFPI), which regulates the tissue factor-dependent pathway of blood coagulation, is released from the endothelium by heparin, a mechanism contributing to its antithrombotic activity. Heparin 150-157 tissue factor pathway inhibitor Homo sapiens 33-37 9798992-2 1998 Tissue factor pathway inhibitor (TFPI), which regulates the tissue factor-dependent pathway of blood coagulation, is released from the endothelium by heparin, a mechanism contributing to its antithrombotic activity. Heparin 150-157 tissue factor pathway inhibitor Homo sapiens 0-31 9798992-3 1998 In this study, we demonstrated that fucoidan, as heparin, induces TFPI release from cultured human umbilical vein endothelial cells (HUVEC). Heparin 49-56 tissue factor pathway inhibitor Homo sapiens 66-70 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 150-157 tissue factor pathway inhibitor Homo sapiens 0-31 10420071-0 1998 Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 112-143 10420071-0 1998 Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor. Heparin 57-64 tissue factor pathway inhibitor Homo sapiens 112-143 10420071-2 1998 Apart from this main action release of tissue factor pathway inhibitor (TFPI) from endothelial cells could also be important for the antithrombotic activity of heparins. Heparin 160-168 tissue factor pathway inhibitor Homo sapiens 39-70 10420071-2 1998 Apart from this main action release of tissue factor pathway inhibitor (TFPI) from endothelial cells could also be important for the antithrombotic activity of heparins. Heparin 160-168 tissue factor pathway inhibitor Homo sapiens 72-76 15992020-5 1998 The inhibitory action of TFPI is accelerated by heparin. Heparin 48-55 tissue factor pathway inhibitor Homo sapiens 25-29 15992020-6 1998 Heparin, as well as low molecular weight heparin (LMWH) derivatives, release TFPI from the vascular endothelium, an effect which seems to contribute mainly to the antithrombotic effectiveness of these drugs. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 77-81 15992020-6 1998 Heparin, as well as low molecular weight heparin (LMWH) derivatives, release TFPI from the vascular endothelium, an effect which seems to contribute mainly to the antithrombotic effectiveness of these drugs. Heparin 41-48 tissue factor pathway inhibitor Homo sapiens 77-81 9819002-0 1998 A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans. Heparin 37-44 tissue factor pathway inhibitor Homo sapiens 96-127 9819002-1 1998 Unfractionated as well as low-molecular-weight heparins (LMWH) are known to cause an increase in blood levels of tissue factor pathway inhibitor (TFPI). Heparin 47-55 tissue factor pathway inhibitor Homo sapiens 113-144 9819002-1 1998 Unfractionated as well as low-molecular-weight heparins (LMWH) are known to cause an increase in blood levels of tissue factor pathway inhibitor (TFPI). Heparin 47-55 tissue factor pathway inhibitor Homo sapiens 146-150 9736420-0 1998 Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Heparin 45-52 tissue factor pathway inhibitor Homo sapiens 122-153 9736420-0 1998 Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Heparin 45-52 tissue factor pathway inhibitor Homo sapiens 155-159 9736420-0 1998 Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Heparin 72-79 tissue factor pathway inhibitor Homo sapiens 122-153 9736420-0 1998 Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Heparin 72-79 tissue factor pathway inhibitor Homo sapiens 155-159 9736420-2 1998 Heparin exerts its function by potentiating antithrombin and by mobilizing tissue factor pathway inhibitor (TFPI) into the circulation. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 75-106 9736420-2 1998 Heparin exerts its function by potentiating antithrombin and by mobilizing tissue factor pathway inhibitor (TFPI) into the circulation. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 108-112 9736420-6 1998 Infusion of UFH, but not subcutaneous LMWH, was found to attenuate the antithrombotic defense by a selective decrease of both circulating antithrombin (-21+/-7%, p<0.0001) and of free and endothelial-bound TFPI. Heparin 12-15 tissue factor pathway inhibitor Homo sapiens 209-213 9736420-8 1998 The differential effect of UFH and LMWH on antithrombin and TFPI may explain the superior efficacy of subcutaneous LMWH compared with conventional intravenous UFH for treatment of both arterial and venous thrombosis. Heparin 27-30 tissue factor pathway inhibitor Homo sapiens 60-64 9674734-2 1998 In the present study we investigated whether subcutaneous (s.c.) administration of a low molecular weight heparin (LMWH), enoxaparin, had a different effect on intravascular pools of TFPI compared with continuous i.v. Heparin 106-113 tissue factor pathway inhibitor Homo sapiens 183-187 9674734-6 1998 caused an 8-13-fold increase in plasma-free TFPI antigen (TFPI Ag), followed by a progressive decrease (81 +/- 4%, P<0.001) during the 72 h infusion with UFH. Heparin 157-160 tissue factor pathway inhibitor Homo sapiens 44-48 9674734-6 1998 caused an 8-13-fold increase in plasma-free TFPI antigen (TFPI Ag), followed by a progressive decrease (81 +/- 4%, P<0.001) during the 72 h infusion with UFH. Heparin 157-160 tissue factor pathway inhibitor Homo sapiens 58-62 9674734-7 1998 4 h after discontinuation of the infusion, basal free TFPI Ag and heparin-releasable TFPI were significantly decreased compared with the concentrations before the infusion (30 +/- 9%, and 27 +/- 7%, respectively). Heparin 66-73 tissue factor pathway inhibitor Homo sapiens 85-89 9674734-9 1998 The changes in plasma TFPI Ag by UFH and LMWH were statistically different between groups both in pre- (P<0.001) and post-heparin (P<0.0001) plasma. Heparin 33-36 tissue factor pathway inhibitor Homo sapiens 22-26 9674734-9 1998 The changes in plasma TFPI Ag by UFH and LMWH were statistically different between groups both in pre- (P<0.001) and post-heparin (P<0.0001) plasma. Heparin 125-132 tissue factor pathway inhibitor Homo sapiens 22-26 9674734-10 1998 The differential effect of UFH and LMWH on intravascular pools of TFPI may contribute to the understanding of the apparent superior efficacy of LMWHs in the treatment of both arterial and venous thrombosis. Heparin 27-30 tissue factor pathway inhibitor Homo sapiens 66-70 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 150-157 tissue factor pathway inhibitor Homo sapiens 33-37 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 237-244 tissue factor pathway inhibitor Homo sapiens 0-31 9674734-1 1998 Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor (TF)-induced blood coagulation, which is increased several-fold in post-heparin plasma and thought to contribute significantly to the antithrombotic action of heparin. Heparin 237-244 tissue factor pathway inhibitor Homo sapiens 33-37 9359432-8 1997 When HepG2 cells are washed with heparin or dextran sulphate, a substance that binds TFPI is removed from the cell surface and can be detected in a slot-blot assay. Heparin 33-40 tissue factor pathway inhibitor Homo sapiens 85-89 9622039-7 1998 TFPI increased 2.3 times following dialysis and such an increase was directly correlated with post-dialysis plasma heparin concentration (r=0.571, p=0.0002) and inversely correlated with post-dialysis triglyceride variation (r=0.407, p=0.005). Heparin 115-122 tissue factor pathway inhibitor Homo sapiens 0-4 9622042-0 1998 Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 47-78 9622042-0 1998 Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 80-84 9622042-4 1998 Heparin-releasable TFPI level in the coronary spastic angina group significantly increased in the coronary sinus (1 22+/-46 to 147+/-63, p<0.001) after the ischemic event but not in the aortic root (113+/-44 to 121+/-58). Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 19-23 9622042-6 1998 The coronary sinus-arterial difference in the amount of the heparin-releasable TFPI significantly increased after the ischemic event only in the coronary spastic angina group (10+/-18 to 26+/-18, p<0.002). Heparin 60-67 tissue factor pathway inhibitor Homo sapiens 79-83 9622042-7 1998 Our result suggested that heparin-releasable TFPI is increased in the coronary circulation after coronary spasm. Heparin 26-33 tissue factor pathway inhibitor Homo sapiens 45-49 9345040-7 1997 The binding of exogenously added 125I-TFPI increased linearly to HUVEC over the concentration range of 0 to 32 nmol/L without saturation, the binding was not affected by up to a thousand-fold molar excess of unlabeled TFPI, and heparin inhibited the binding dose dependently. Heparin 228-235 tissue factor pathway inhibitor Homo sapiens 38-42 9669748-0 1998 Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction. Heparin 76-83 tissue factor pathway inhibitor Homo sapiens 88-92 9669748-1 1998 Heparin affinity chromatography of synthetic peptide fragments mimicking tissue factor pathway inhibitor (TFPI) indicated that the minimal heparin binding sequence consists of 12 amino acid residues located at the C-terminal tail. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 73-104 9669748-1 1998 Heparin affinity chromatography of synthetic peptide fragments mimicking tissue factor pathway inhibitor (TFPI) indicated that the minimal heparin binding sequence consists of 12 amino acid residues located at the C-terminal tail. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 106-110 9669748-1 1998 Heparin affinity chromatography of synthetic peptide fragments mimicking tissue factor pathway inhibitor (TFPI) indicated that the minimal heparin binding sequence consists of 12 amino acid residues located at the C-terminal tail. Heparin 139-146 tissue factor pathway inhibitor Homo sapiens 73-104 9669748-1 1998 Heparin affinity chromatography of synthetic peptide fragments mimicking tissue factor pathway inhibitor (TFPI) indicated that the minimal heparin binding sequence consists of 12 amino acid residues located at the C-terminal tail. Heparin 139-146 tissue factor pathway inhibitor Homo sapiens 106-110 9669748-3 1998 Affinity chromatography of TFPI using immobilized heparin derivatives regiospecifically desulfated at O-6 of the glucosamine residue, N-2 of the glucosamine residue, and/or O-2 of the iduronic acid residue indicated that all the sulfate groups in heparin appeared to be required for TFPI-heparin interaction. Heparin 50-57 tissue factor pathway inhibitor Homo sapiens 27-31 9669748-3 1998 Affinity chromatography of TFPI using immobilized heparin derivatives regiospecifically desulfated at O-6 of the glucosamine residue, N-2 of the glucosamine residue, and/or O-2 of the iduronic acid residue indicated that all the sulfate groups in heparin appeared to be required for TFPI-heparin interaction. Heparin 50-57 tissue factor pathway inhibitor Homo sapiens 283-287 9669748-3 1998 Affinity chromatography of TFPI using immobilized heparin derivatives regiospecifically desulfated at O-6 of the glucosamine residue, N-2 of the glucosamine residue, and/or O-2 of the iduronic acid residue indicated that all the sulfate groups in heparin appeared to be required for TFPI-heparin interaction. Heparin 247-254 tissue factor pathway inhibitor Homo sapiens 27-31 9669748-3 1998 Affinity chromatography of TFPI using immobilized heparin derivatives regiospecifically desulfated at O-6 of the glucosamine residue, N-2 of the glucosamine residue, and/or O-2 of the iduronic acid residue indicated that all the sulfate groups in heparin appeared to be required for TFPI-heparin interaction. Heparin 247-254 tissue factor pathway inhibitor Homo sapiens 27-31 9669748-5 1998 In vitro experiments on the inhibition of factor Xa by TFPI enhanced with native and chemically modified heparins afforded similar results. Heparin 105-113 tissue factor pathway inhibitor Homo sapiens 55-59 9622211-1 1998 Low-molecular-mass heparins (LMMHs) exert an anti-FXa effect through antithrombin III (ATIII) and tissue factor pathway inhibitor (TFPI) displaced from endothelium and lipoproteins. Heparin 19-27 tissue factor pathway inhibitor Homo sapiens 98-129 9622211-1 1998 Low-molecular-mass heparins (LMMHs) exert an anti-FXa effect through antithrombin III (ATIII) and tissue factor pathway inhibitor (TFPI) displaced from endothelium and lipoproteins. Heparin 19-27 tissue factor pathway inhibitor Homo sapiens 131-135 9651145-8 1998 These results suggest that in the presence of heparin, antithrombin III interferes with the catabolism of TFPI mediated via Xa. Heparin 46-53 tissue factor pathway inhibitor Homo sapiens 106-110 8865534-10 1996 The concentration of TFPI was significantly increased following the incubation with thrombin and heparin, including low molecular weight heparin, in a dose- and time-dependent manner. Heparin 97-104 tissue factor pathway inhibitor Homo sapiens 21-25 9187023-0 1997 The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man. Heparin 156-163 tissue factor pathway inhibitor Homo sapiens 43-74 9187023-3 1997 Tissue factor pathway inhibitor (TFPI) is an endogenous heparin releasable three domain Kunitz-type coagulation inhibitor which inhibits the crucial tissue factor-factor VIIa (TF-FVIIa) dependent coagulation pathway in the presence of FXa. Heparin 56-63 tissue factor pathway inhibitor Homo sapiens 0-31 9187023-3 1997 Tissue factor pathway inhibitor (TFPI) is an endogenous heparin releasable three domain Kunitz-type coagulation inhibitor which inhibits the crucial tissue factor-factor VIIa (TF-FVIIa) dependent coagulation pathway in the presence of FXa. Heparin 56-63 tissue factor pathway inhibitor Homo sapiens 33-37 9187023-5 1997 TFPI is located to different vascular pools, the largest being the vascular endothelium from where TFPI can be released dose-dependently to the blood by heparins (2). Heparin 153-161 tissue factor pathway inhibitor Homo sapiens 0-4 9187023-5 1997 TFPI is located to different vascular pools, the largest being the vascular endothelium from where TFPI can be released dose-dependently to the blood by heparins (2). Heparin 153-161 tissue factor pathway inhibitor Homo sapiens 99-103 9187023-6 1997 TFPI is speculated to contribute to the anticoagulant properties of heparins, but to which degree is not yet fully understood. Heparin 68-76 tissue factor pathway inhibitor Homo sapiens 0-4 9200336-8 1997 In contrast, after heparin a significantly lower rise in TFPI antigen plasma levels was observed in obese patients (511.2 +/- 43.4 ng/mL) (p < 0.003). Heparin 19-26 tissue factor pathway inhibitor Homo sapiens 57-61 9200336-9 1997 Moreover, a significant inverse correlation was found between the heparin-stimulated TFPI antigen plasma levels and both BMI and basal plasma insulin concentrations. Heparin 66-73 tissue factor pathway inhibitor Homo sapiens 85-89 8865534-10 1996 The concentration of TFPI was significantly increased following the incubation with thrombin and heparin, including low molecular weight heparin, in a dose- and time-dependent manner. Heparin 137-144 tissue factor pathway inhibitor Homo sapiens 21-25 27406868-0 1997 The Release of Tissue Factor Pathway Inhibitor and Platelet Factor 4 After Heparin Injection in Patients with Thrombocytosis. Heparin 75-82 tissue factor pathway inhibitor Homo sapiens 15-46 27406868-1 1997 Platelet factor 4 (PF4) and tissue factor pathway inhibitor (TFPI) are two proteins with high affinity for heparin. Heparin 107-114 tissue factor pathway inhibitor Homo sapiens 28-59 9156410-0 1997 Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration. Heparin 120-127 tissue factor pathway inhibitor Homo sapiens 0-31 9156410-0 1997 Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration. Heparin 120-127 tissue factor pathway inhibitor Homo sapiens 33-37 9156410-6 1997 Five minutes after heparin administration the rise in TFPI was lower, although not statistically significant, in all sarcoidosis stages than in controls. Heparin 19-26 tissue factor pathway inhibitor Homo sapiens 54-58 9156410-8 1997 In sarcoidosis the elevated TFPI and the lower capacity by endothelial cells to release TFPI after heparin may represent a compensatory mechanism to prevent blood clotting and/or the endothelial cell dysfunction of the microvasculature in this condition. Heparin 99-106 tissue factor pathway inhibitor Homo sapiens 88-92 8948048-0 1996 The effect of heparin and its neutralisation on functional assays for factor VIIa, factor VII and TFPI. Heparin 14-21 tissue factor pathway inhibitor Homo sapiens 70-102 8948048-7 1996 In the amidolytic substrate assays for TFPI and FVII, heparin with or without neutralisation resulted in only small changes in the optical density at 405nm and hence plasma levels of these factors were not significantly changed. Heparin 54-61 tissue factor pathway inhibitor Homo sapiens 39-43 8950772-8 1996 The post-dye levels of TFPI activity were significantly increased in the former group due to the heparin-induced release of TFPI. Heparin 97-104 tissue factor pathway inhibitor Homo sapiens 23-27 8950772-8 1996 The post-dye levels of TFPI activity were significantly increased in the former group due to the heparin-induced release of TFPI. Heparin 97-104 tissue factor pathway inhibitor Homo sapiens 124-128 8950777-0 1996 Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Heparin 129-136 tissue factor pathway inhibitor Homo sapiens 36-67 8950777-0 1996 Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Heparin 129-136 tissue factor pathway inhibitor Homo sapiens 69-73 8950777-2 1996 TFPI is increased several-fold in postheparin plasma and thereby thought to contribute significantly to the antithrombotic action of heparin. Heparin 38-45 tissue factor pathway inhibitor Homo sapiens 0-4 8950777-3 1996 The present study was conducted to investigate how repeated (n = 8) and continuous (n = 6) administration of heparin affect plasma TFPI and the inhibition of tissue factor (TF)-induced coagulation ex vivo in humans. Heparin 109-116 tissue factor pathway inhibitor Homo sapiens 131-135 8950777-4 1996 Free TFPI antigen (TFPI Ag) increased from 19.2 +/- 4.0 ng/ml to 204.7 +/- 31.7 ng/ml after intravenous injection of 5000 IU of unfractionated heparin. Heparin 143-150 tissue factor pathway inhibitor Homo sapiens 5-9 8950777-4 1996 Free TFPI antigen (TFPI Ag) increased from 19.2 +/- 4.0 ng/ml to 204.7 +/- 31.7 ng/ml after intravenous injection of 5000 IU of unfractionated heparin. Heparin 143-150 tissue factor pathway inhibitor Homo sapiens 19-23 8950777-5 1996 Five repeated injections of 5000 IU of heparin at 4 h intervals caused a progressive decrease (-45 +/- 8%, p < 0.0001 for time effect) in heparin-releasable TFPI and a progressive shortening of the clotting time as determined in a dilute prothrombin time assay (dPT) (-8.7 +/- 6.1 s, p < 0.0001). Heparin 39-46 tissue factor pathway inhibitor Homo sapiens 160-164 8950777-5 1996 Five repeated injections of 5000 IU of heparin at 4 h intervals caused a progressive decrease (-45 +/- 8%, p < 0.0001 for time effect) in heparin-releasable TFPI and a progressive shortening of the clotting time as determined in a dilute prothrombin time assay (dPT) (-8.7 +/- 6.1 s, p < 0.0001). Heparin 141-148 tissue factor pathway inhibitor Homo sapiens 160-164 8950777-6 1996 The basal concentration of TFPI Ag in plasma collected immediately before each heparin injection was decreased by 29 +/- 15% (p < 0.0001), whereas the dPT was decreased by 6.9 +/- 3.5 s (p < 0.0001). Heparin 79-86 tissue factor pathway inhibitor Homo sapiens 27-31 8950777-8 1996 The contribution of TFPI to the inhibition of TF-induced coagulation during heparin infusion was estimated to decrease from 60 +/- 15% to 20 +/- 10% (p < 0.0001). Heparin 76-83 tissue factor pathway inhibitor Homo sapiens 20-24 8950777-9 1996 The present data indicate partial depletion of intravascular pools of TFPI by repeated and continuous heparin administration and thereby attenuation of its contribution to the antithrombotic action of heparin. Heparin 102-109 tissue factor pathway inhibitor Homo sapiens 70-74 8950777-9 1996 The present data indicate partial depletion of intravascular pools of TFPI by repeated and continuous heparin administration and thereby attenuation of its contribution to the antithrombotic action of heparin. Heparin 201-208 tissue factor pathway inhibitor Homo sapiens 70-74 8979119-5 1996 Current research on TFPI is mainly focused on the cell biology of TFPI, on the contribution of TFPI to the anticoagulant action of heparins, and on the role of lipoprotein-associated TFPI. Heparin 131-139 tissue factor pathway inhibitor Homo sapiens 20-24 8979119-7 1996 The binding molecule(s) have not yet been characterized, but TFPI is rapidly released by heparin and other negatively charged ions. Heparin 89-96 tissue factor pathway inhibitor Homo sapiens 61-65 8979119-11 1996 Moreover, in the presence of heparin, antithrombin and TFPI cooperate to inhibit activation of coagulation. Heparin 29-36 tissue factor pathway inhibitor Homo sapiens 55-59 8874868-8 1996 In the pulmonary vein plasma levels of activated factor VII decreased following heparin administration (P < 0.001) in the majority of patients which was coincidental to an increase (P < 0.001) in tissue factor pathway inhibitor (TFPI). Heparin 80-87 tissue factor pathway inhibitor Homo sapiens 202-233 8874868-8 1996 In the pulmonary vein plasma levels of activated factor VII decreased following heparin administration (P < 0.001) in the majority of patients which was coincidental to an increase (P < 0.001) in tissue factor pathway inhibitor (TFPI). Heparin 80-87 tissue factor pathway inhibitor Homo sapiens 235-239 8739535-4 1996 Heparin produced a marked release of TFPI and t-PA after i.v. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 37-41 8725726-4 1996 The presence of heparin (1 U/ml, unfractionated) was able to significantly reduce the binding of TFPI to phospholipid. Heparin 16-23 tissue factor pathway inhibitor Homo sapiens 97-101 8868518-7 1996 One hundred eighty minutes after initiation of dialysis, by which time all patients were receiving heparin there was a further increase in TFPI (to more than 200% of baseline), due to the presence of the glycosaminoglycan. Heparin 99-106 tissue factor pathway inhibitor Homo sapiens 139-143 8868518-8 1996 This was due the previously reported displacement by heparin of the major intravascular pool of TFPI, from endothelial cell surfaces. Heparin 53-60 tissue factor pathway inhibitor Homo sapiens 96-100 8640408-7 1996 We applied this new method to measure the amount of endothelial cell-associated TFPI, which can be released by heparin injection, as "free-form TFPI." Heparin 111-118 tissue factor pathway inhibitor Homo sapiens 80-84 8640408-7 1996 We applied this new method to measure the amount of endothelial cell-associated TFPI, which can be released by heparin injection, as "free-form TFPI." Heparin 111-118 tissue factor pathway inhibitor Homo sapiens 144-148 8840000-0 1996 The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Heparin 14-21 tissue factor pathway inhibitor Homo sapiens 81-112 8840000-2 1996 Previous studies have shown that heparin binds to TFPI at two sites and enhances the inhibitory activity of TFPI towards factor Xa. Heparin 33-40 tissue factor pathway inhibitor Homo sapiens 50-54 8840000-2 1996 Previous studies have shown that heparin binds to TFPI at two sites and enhances the inhibitory activity of TFPI towards factor Xa. Heparin 33-40 tissue factor pathway inhibitor Homo sapiens 108-112 8840000-3 1996 We have studied the effect of heparin of the TFPI-mediated inhibition of factor VIIa-relipidated tissue factor amiodolytic activity and factor VIIa-tissue factor proteolytic activity towards factor IX and factor X on a human bladder carcinoma cell line, J82. Heparin 30-37 tissue factor pathway inhibitor Homo sapiens 45-49 8840000-4 1996 The inhibitory activity of full-length TFPI on factor VIIa-tissue factor amidolytic and proteolytic activities was greatly enhanced by heparin, whereas the inhibitory activity of a truncated form of TFPI lacking the third Kunitz-type domain and carboxy-terminal tail (TFPI1-161) was not affected by heparin. Heparin 135-142 tissue factor pathway inhibitor Homo sapiens 39-43 8840000-5 1996 Optimal inhibition of factor VIIa-tissue factor by TFPI was observed at 0.1 U/ml heparin. Heparin 81-88 tissue factor pathway inhibitor Homo sapiens 51-55 8840000-6 1996 Heparin enhanced the inhibitory activity of TFPI towards factor Xa even in the presence of factor VIIa-tissue factor complexes in solution phase. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 44-48 8840000-7 1996 In addition, heparin augmented the ability of TFPI to inhibit factor VIIa-tissue factor amidolytic activity in the presence of active-site mutated factor X (S376A factor X). Heparin 13-20 tissue factor pathway inhibitor Homo sapiens 46-50 8840000-8 1996 Our collective results suggest that heparin may play a significant role in augmenting the physiological regulation of factor VIIa-tissue factor activity by TFPI. Heparin 36-43 tissue factor pathway inhibitor Homo sapiens 156-160 8840001-0 1996 Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin. Heparin 100-107 tissue factor pathway inhibitor Homo sapiens 26-57 8840001-1 1996 The present study was designed to investigate the anticoagulant action of inhaled low-molecular-weight (LMW) heparin on the release of tissue factor pathway inhibitor (TFPI) and on antifactor Xa activity, Heptest, activated partial thromboplastin time (APTT) and thrombin clotting time (TCT) in healthy volunteers. Heparin 109-116 tissue factor pathway inhibitor Homo sapiens 135-166 8840001-1 1996 The present study was designed to investigate the anticoagulant action of inhaled low-molecular-weight (LMW) heparin on the release of tissue factor pathway inhibitor (TFPI) and on antifactor Xa activity, Heptest, activated partial thromboplastin time (APTT) and thrombin clotting time (TCT) in healthy volunteers. Heparin 109-116 tissue factor pathway inhibitor Homo sapiens 168-172 8630391-2 1996 At near-plasma concentrations of TFPI, ATIII, and factor X, factor X activation that occurs in response to TF:VII is essentially abolished in the presence of heparin (0.5 micromol/L). Heparin 158-165 tissue factor pathway inhibitor Homo sapiens 33-37 8630391-6 1996 These results indicated that when the unactivated TF:VII complex is the initiating stimulus, heparin-dependent reduction in the rate and extent of factor X activation requires both ATIII and TFPI. Heparin 93-100 tissue factor pathway inhibitor Homo sapiens 191-195 8634431-3 1996 When factor Xa is added to mixtures containing TFPI, prothrombin, calcium ions, and nonactivated platelets or factor V and phospholipids, TFPI significantly reduces subsequent thrombin generation, and the inhibitory effect is enhanced by heparin. Heparin 238-245 tissue factor pathway inhibitor Homo sapiens 47-51 8634431-3 1996 When factor Xa is added to mixtures containing TFPI, prothrombin, calcium ions, and nonactivated platelets or factor V and phospholipids, TFPI significantly reduces subsequent thrombin generation, and the inhibitory effect is enhanced by heparin. Heparin 238-245 tissue factor pathway inhibitor Homo sapiens 138-142 8739535-12 1996 Repeated administration of a hypersulfated heparin analogue produced marked increase in TFPI in both i.v. Heparin 43-50 tissue factor pathway inhibitor Homo sapiens 88-92 8907299-5 1996 Moreover, it is clearly established that both kinds of heparins (unfractionated heparin and LMWHs) induce the release of tissue factor pathway inhibitor (TFPI). Heparin 55-63 tissue factor pathway inhibitor Homo sapiens 121-152 8907299-5 1996 Moreover, it is clearly established that both kinds of heparins (unfractionated heparin and LMWHs) induce the release of tissue factor pathway inhibitor (TFPI). Heparin 55-63 tissue factor pathway inhibitor Homo sapiens 154-158 8907299-5 1996 Moreover, it is clearly established that both kinds of heparins (unfractionated heparin and LMWHs) induce the release of tissue factor pathway inhibitor (TFPI). Heparin 55-62 tissue factor pathway inhibitor Homo sapiens 121-152 8907299-5 1996 Moreover, it is clearly established that both kinds of heparins (unfractionated heparin and LMWHs) induce the release of tissue factor pathway inhibitor (TFPI). Heparin 55-62 tissue factor pathway inhibitor Homo sapiens 154-158 9112630-5 1996 The interaction of TFPI with heparin has been demonstrated. Heparin 29-36 tissue factor pathway inhibitor Homo sapiens 19-23 8548430-17 1996 However, it would be interesting to study the increased levels of endothelium-derived TFPI in plasma induced by the injection of heparin. Heparin 129-136 tissue factor pathway inhibitor Homo sapiens 86-90 9112630-6 1996 The heparin binding site of TFPI (HBS-1) locates in its C-terminal basic portion. Heparin 4-11 tissue factor pathway inhibitor Homo sapiens 28-32 9112630-7 1996 We found another heparin-binding site in K3 domain of TFPI, using each of the three Kunitz domains prepared by the limited cleavage of TFPI and also synthetic peptides mimicking the amino acid sequence of a Kunitz domain. Heparin 17-24 tissue factor pathway inhibitor Homo sapiens 54-58 9112630-7 1996 We found another heparin-binding site in K3 domain of TFPI, using each of the three Kunitz domains prepared by the limited cleavage of TFPI and also synthetic peptides mimicking the amino acid sequence of a Kunitz domain. Heparin 17-24 tissue factor pathway inhibitor Homo sapiens 135-139 9112630-8 1996 These heparin binding sites of TFPI will play an important role for the association with endothelial cells, interacting with heparin sulphate on the surface. Heparin 6-13 tissue factor pathway inhibitor Homo sapiens 31-35 8585041-0 1995 Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Heparin 104-111 tissue factor pathway inhibitor Homo sapiens 18-49 8588202-4 1995 The release of TFPI, after heparin administration, was proportionally reduced in the two siblings as compared with controls. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 15-19 8585041-3 1995 TFPI readily inhibited APC amidolytic activity only in the presence of heparin, whereas TFPI1-161 failed to inhibit APC amidolytic activity in the presence or absence of heparin. Heparin 71-78 tissue factor pathway inhibitor Homo sapiens 0-4 8585041-4 1995 Optimal inhibition of APC by TFPI was observed at 1 U/ml heparin. Heparin 57-64 tissue factor pathway inhibitor Homo sapiens 29-33 8585041-5 1995 The results of competition studies between factor Xa and APC for inhibition by TFPI in the presence of heparin suggested that the second Kunitz-type domain in TFPI was responsible for the inhibition of APC. Heparin 103-110 tissue factor pathway inhibitor Homo sapiens 79-83 8585041-5 1995 The results of competition studies between factor Xa and APC for inhibition by TFPI in the presence of heparin suggested that the second Kunitz-type domain in TFPI was responsible for the inhibition of APC. Heparin 103-110 tissue factor pathway inhibitor Homo sapiens 159-163 8533128-0 1995 Effect of protamine on heparin releasable TFPI antigen levels in normal volunteers. Heparin 23-30 tissue factor pathway inhibitor Homo sapiens 42-46 7600119-2 1995 A major pool of TFPI is associated with the vascular endothelium and can be mobilized into the circulation by heparin. Heparin 110-117 tissue factor pathway inhibitor Homo sapiens 16-20 7600119-4 1995 In this study, heparin administration caused a 2.2-fold and a 7.5-fold increase in TFPI activity and TFPI antigen, respectively, in 25 patients with phenotypes IIa and IIb hyperbetalipoproteinemia. Heparin 15-22 tissue factor pathway inhibitor Homo sapiens 83-87 7600119-4 1995 In this study, heparin administration caused a 2.2-fold and a 7.5-fold increase in TFPI activity and TFPI antigen, respectively, in 25 patients with phenotypes IIa and IIb hyperbetalipoproteinemia. Heparin 15-22 tissue factor pathway inhibitor Homo sapiens 101-105 7600119-5 1995 Because the antigen determination of TFPI almost exclusively measures carrier-free TFPI, more than 90% of the heparin-induced increase in TFPI activity was caused by mobilization of carrier-free TFPI from the vascular endothelium. Heparin 110-117 tissue factor pathway inhibitor Homo sapiens 37-41 7600119-5 1995 Because the antigen determination of TFPI almost exclusively measures carrier-free TFPI, more than 90% of the heparin-induced increase in TFPI activity was caused by mobilization of carrier-free TFPI from the vascular endothelium. Heparin 110-117 tissue factor pathway inhibitor Homo sapiens 83-87 7600119-5 1995 Because the antigen determination of TFPI almost exclusively measures carrier-free TFPI, more than 90% of the heparin-induced increase in TFPI activity was caused by mobilization of carrier-free TFPI from the vascular endothelium. Heparin 110-117 tissue factor pathway inhibitor Homo sapiens 83-87 7600119-5 1995 Because the antigen determination of TFPI almost exclusively measures carrier-free TFPI, more than 90% of the heparin-induced increase in TFPI activity was caused by mobilization of carrier-free TFPI from the vascular endothelium. Heparin 110-117 tissue factor pathway inhibitor Homo sapiens 83-87 7647220-6 1995 Heparin strongly accelerates AT and releases TFPI to the blood. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 45-49 21232254-3 1995 The acceleration of TFPI"s inhibitory effect by heparin, the TFPI release caused by heparin injection, and TFPI"s heparin affinity may greatly contribute to the anticoagulant properties of the endothelium, and may be particularly important for the outcome of vascular injury. Heparin 48-55 tissue factor pathway inhibitor Homo sapiens 20-24 21232254-3 1995 The acceleration of TFPI"s inhibitory effect by heparin, the TFPI release caused by heparin injection, and TFPI"s heparin affinity may greatly contribute to the anticoagulant properties of the endothelium, and may be particularly important for the outcome of vascular injury. Heparin 84-91 tissue factor pathway inhibitor Homo sapiens 61-65 21232254-3 1995 The acceleration of TFPI"s inhibitory effect by heparin, the TFPI release caused by heparin injection, and TFPI"s heparin affinity may greatly contribute to the anticoagulant properties of the endothelium, and may be particularly important for the outcome of vascular injury. Heparin 84-91 tissue factor pathway inhibitor Homo sapiens 61-65 21232254-3 1995 The acceleration of TFPI"s inhibitory effect by heparin, the TFPI release caused by heparin injection, and TFPI"s heparin affinity may greatly contribute to the anticoagulant properties of the endothelium, and may be particularly important for the outcome of vascular injury. Heparin 84-91 tissue factor pathway inhibitor Homo sapiens 61-65 21232254-3 1995 The acceleration of TFPI"s inhibitory effect by heparin, the TFPI release caused by heparin injection, and TFPI"s heparin affinity may greatly contribute to the anticoagulant properties of the endothelium, and may be particularly important for the outcome of vascular injury. Heparin 84-91 tissue factor pathway inhibitor Homo sapiens 61-65 7647223-4 1995 With the identification of tissue factor pathway inhibitor (TFPI) some of the unexpected effects of heparins can now be clarified. Heparin 100-108 tissue factor pathway inhibitor Homo sapiens 27-58 7647223-4 1995 With the identification of tissue factor pathway inhibitor (TFPI) some of the unexpected effects of heparins can now be clarified. Heparin 100-108 tissue factor pathway inhibitor Homo sapiens 60-64 7647222-0 1995 Tissue factor pathway inhibitor: proposed heparin recognition region. Heparin 42-49 tissue factor pathway inhibitor Homo sapiens 0-31 7647223-5 1995 To investigate the role of heparin-releasable TFPI on LMWHs the anti-Xa and TFPI antigen levels after prophylactic and therapeutic administration of UFH and LMWHs have been studied in defined clinical trials. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 46-50 7647222-1 1995 After intravenous and subcutaneous injection, heparins and low-molecular-weight heparins release tissue factor pathway inhibitor (TFPI) into the blood stream. Heparin 46-54 tissue factor pathway inhibitor Homo sapiens 97-128 7647222-1 1995 After intravenous and subcutaneous injection, heparins and low-molecular-weight heparins release tissue factor pathway inhibitor (TFPI) into the blood stream. Heparin 46-54 tissue factor pathway inhibitor Homo sapiens 130-134 7647222-7 1995 This proposed heparin recognition region in TFPI is similar to the recognition region in antithrombin III and other proteins. Heparin 14-21 tissue factor pathway inhibitor Homo sapiens 44-48 7647222-9 1995 A comparison of a helical wheel diagram of antithrombin III and tissue factor pathway inhibitor support also the proposal of this form of a heparin recognition region in TFPI. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 64-95 7647222-9 1995 A comparison of a helical wheel diagram of antithrombin III and tissue factor pathway inhibitor support also the proposal of this form of a heparin recognition region in TFPI. Heparin 140-147 tissue factor pathway inhibitor Homo sapiens 170-174 7647223-0 1995 The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Heparin 94-101 tissue factor pathway inhibitor Homo sapiens 12-43 7647223-0 1995 The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Heparin 127-134 tissue factor pathway inhibitor Homo sapiens 12-43 7726132-10 1995 In patients with cardiovascular disease, a 7-day treatment with subcutaneous standard heparin increased TFPI activity. Heparin 86-93 tissue factor pathway inhibitor Homo sapiens 104-108 7727433-0 1995 Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Heparin 10-17 tissue factor pathway inhibitor Homo sapiens 52-83 7727433-0 1995 Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Heparin 143-150 tissue factor pathway inhibitor Homo sapiens 52-83 7706485-7 1995 Full-length 125I-TFPI binding to hepatoma cells could be inhibited > 90% by heparin and other highly charged molecules. Heparin 79-86 tissue factor pathway inhibitor Homo sapiens 17-21 7605876-2 1995 Heparin injection has previously been shown to increase the plasma levels of TFPI. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 77-81 7712048-2 1994 The knowledge of the relationship between the structure and function of the tissue factor pathway inhibitor molecule has been widely expanded, especially with regard to its interaction with heparin. Heparin 190-197 tissue factor pathway inhibitor Homo sapiens 76-107 7740509-0 1995 TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Heparin 115-122 tissue factor pathway inhibitor Homo sapiens 0-4 7740509-0 1995 TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Heparin 150-157 tissue factor pathway inhibitor Homo sapiens 0-4 7740509-1 1995 Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo anticoagulant/antithrombotic properties of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 137-144 tissue factor pathway inhibitor Homo sapiens 0-31 7740509-1 1995 Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo anticoagulant/antithrombotic properties of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 137-144 tissue factor pathway inhibitor Homo sapiens 33-37 7740509-1 1995 Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo anticoagulant/antithrombotic properties of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 146-149 tissue factor pathway inhibitor Homo sapiens 0-31 7740509-1 1995 Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo anticoagulant/antithrombotic properties of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 146-149 tissue factor pathway inhibitor Homo sapiens 33-37 7740509-1 1995 Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo anticoagulant/antithrombotic properties of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 176-183 tissue factor pathway inhibitor Homo sapiens 0-31 7740509-1 1995 Tissue factor pathway inhibitor (TFPI) is an important mediator of the in vivo anticoagulant/antithrombotic properties of unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Heparin 176-183 tissue factor pathway inhibitor Homo sapiens 33-37 7740509-2 1995 The vascular pool of TFPI is released into the circulation after intravenous and subcutaneous administration of both UFH and LMWH. Heparin 117-120 tissue factor pathway inhibitor Homo sapiens 21-25 7740509-4 1995 Our results demonstrate that the TFPI antigen levels increase upon the intravenous and subcutaneous administration of UFH and Ardeparin. Heparin 118-121 tissue factor pathway inhibitor Homo sapiens 33-37 7740509-7 1995 The plasma concentration of TFPI was increased 0.5-2 fold when UFH or Ardeparin was administered subcutaneously and was 3 fold higher when administered intravenously. Heparin 63-66 tissue factor pathway inhibitor Homo sapiens 28-32 7813818-10 1995 It can be concluded that TFPI activity, especially after stimulation with heparin, is affected by chronic hyperglycemia in diabetic subjects without vascular complications. Heparin 74-81 tissue factor pathway inhibitor Homo sapiens 25-29 7660142-0 1995 Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins. Heparin 120-128 tissue factor pathway inhibitor Homo sapiens 77-108 7660142-14 1995 The endogenous release of TFPI may contribute to the antithrombotic actions of heparin and related glycosaminoglycans. Heparin 79-86 tissue factor pathway inhibitor Homo sapiens 26-30 7660146-5 1995 Compared on the basis of their ability to delay the initiation of and inhibit factor X and prothrombin activation, the anticoagulant effectiveness of 0.5 nM TFPI was greater than those of 10 nM hirudin and approximately 100 nM (0.1 unit/mL) heparin. Heparin 241-248 tissue factor pathway inhibitor Homo sapiens 157-161 7865689-0 1994 Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Heparin 66-73 tissue factor pathway inhibitor Homo sapiens 15-46 7974391-1 1994 Tissue Factor Pathway Inhibitor (TFPI) is a heparin binding protein and injection of heparin causes a release of TFPI to plasma. Heparin 44-51 tissue factor pathway inhibitor Homo sapiens 0-31 7831680-4 1994 The inhibitory activity of TFPI was significantly enhanced when unfractionated heparin was present in the assay system at a concentration of 10 micrograms/ml which did not show any inhibitory effects on protease generation in the same system. Heparin 79-86 tissue factor pathway inhibitor Homo sapiens 27-31 7831680-6 1994 Whereas in the concentration range used (0.3-40 micrograms/ml) these glycosaminoglycans did not inhibit thrombin and factor Xa generation, after supplementation of the system with TFPI a concentration-dependent inhibition of the generation of the proteases up to 40-50% was seen for UFH, LMWH and HS. Heparin 283-286 tissue factor pathway inhibitor Homo sapiens 180-184 7841311-3 1994 The native and recombinant TFPI produced by mammalian cells in tissue culture and the TFPI released by heparin in vivo, however, are 34 kDa. Heparin 103-110 tissue factor pathway inhibitor Homo sapiens 27-31 7841311-3 1994 The native and recombinant TFPI produced by mammalian cells in tissue culture and the TFPI released by heparin in vivo, however, are 34 kDa. Heparin 103-110 tissue factor pathway inhibitor Homo sapiens 86-90 7974391-1 1994 Tissue Factor Pathway Inhibitor (TFPI) is a heparin binding protein and injection of heparin causes a release of TFPI to plasma. Heparin 44-51 tissue factor pathway inhibitor Homo sapiens 33-37 7974391-1 1994 Tissue Factor Pathway Inhibitor (TFPI) is a heparin binding protein and injection of heparin causes a release of TFPI to plasma. Heparin 44-51 tissue factor pathway inhibitor Homo sapiens 113-117 7974391-2 1994 In order to understand the binding between TFPI and heparin in more detail we have in this study looked into some of the heparin characteristics and their importance for the TFPI-heparin interaction. Heparin 52-59 tissue factor pathway inhibitor Homo sapiens 174-178 7974391-2 1994 In order to understand the binding between TFPI and heparin in more detail we have in this study looked into some of the heparin characteristics and their importance for the TFPI-heparin interaction. Heparin 121-128 tissue factor pathway inhibitor Homo sapiens 43-47 7974391-2 1994 In order to understand the binding between TFPI and heparin in more detail we have in this study looked into some of the heparin characteristics and their importance for the TFPI-heparin interaction. Heparin 121-128 tissue factor pathway inhibitor Homo sapiens 174-178 7974391-2 1994 In order to understand the binding between TFPI and heparin in more detail we have in this study looked into some of the heparin characteristics and their importance for the TFPI-heparin interaction. Heparin 121-128 tissue factor pathway inhibitor Homo sapiens 43-47 7974391-2 1994 In order to understand the binding between TFPI and heparin in more detail we have in this study looked into some of the heparin characteristics and their importance for the TFPI-heparin interaction. Heparin 121-128 tissue factor pathway inhibitor Homo sapiens 174-178 7974391-3 1994 We have developed an assay based on the use of heparin-Sepharose micro columns in order to compare small quantities of heparin fractions as well as different glycosaminoglycans on a weight basis for their TFPI binding. Heparin 47-54 tissue factor pathway inhibitor Homo sapiens 205-209 7974391-4 1994 In this assay a glycosaminoglycan in solution compete with heparin-Sepharose for TFPI binding. Heparin 59-66 tissue factor pathway inhibitor Homo sapiens 81-85 7974391-5 1994 Size fractionated heparin was analyzed for binding to TFPI, and a clear dependency on the molecular weight was observed. Heparin 18-25 tissue factor pathway inhibitor Homo sapiens 54-58 7974391-10 1994 A number of different glycosaminoglycans were tested and the following order of TFPI affinity was found: heparin >> dermatan sulphate > heparan sulphate > chondroitin sulphate C. Heparin 105-112 tissue factor pathway inhibitor Homo sapiens 80-84 8029788-4 1994 During hemodialysis sessions using heparin, TFPI levels increased 1.2- to 3.5-fold compared with the level before hemodialysis and the degree of increase in TFPI was correlated with the heparin concentration (r = 0.648, p = 0.0001, n = 29). Heparin 35-42 tissue factor pathway inhibitor Homo sapiens 44-48 8029808-0 1994 Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. Heparin 144-151 tissue factor pathway inhibitor Homo sapiens 8-39 8123656-8 1994 After the monkeys received heparin infusions TFPI was increased about fivefold, but there was no significant difference in these increases between normal and hypercholesterolemic monkeys. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 45-49 8123656-9 1994 The increase in TFPI after heparin infusion is discussed in terms of the relationship between lipoprotein-associated TFPI in plasma and endothelial cell-associated TFPI. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 16-20 8123656-9 1994 The increase in TFPI after heparin infusion is discussed in terms of the relationship between lipoprotein-associated TFPI in plasma and endothelial cell-associated TFPI. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 117-121 8123656-9 1994 The increase in TFPI after heparin infusion is discussed in terms of the relationship between lipoprotein-associated TFPI in plasma and endothelial cell-associated TFPI. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 117-121 7959358-9 1994 Another important difference between in vitro and in vivo studies lies in the fact that sc injection of both heparins will release tissue factor pathway inhibitor (TFPI) in the blood. Heparin 109-117 tissue factor pathway inhibitor Homo sapiens 131-162 7959358-9 1994 Another important difference between in vitro and in vivo studies lies in the fact that sc injection of both heparins will release tissue factor pathway inhibitor (TFPI) in the blood. Heparin 109-117 tissue factor pathway inhibitor Homo sapiens 164-168 8029788-4 1994 During hemodialysis sessions using heparin, TFPI levels increased 1.2- to 3.5-fold compared with the level before hemodialysis and the degree of increase in TFPI was correlated with the heparin concentration (r = 0.648, p = 0.0001, n = 29). Heparin 35-42 tissue factor pathway inhibitor Homo sapiens 157-161 8029788-4 1994 During hemodialysis sessions using heparin, TFPI levels increased 1.2- to 3.5-fold compared with the level before hemodialysis and the degree of increase in TFPI was correlated with the heparin concentration (r = 0.648, p = 0.0001, n = 29). Heparin 186-193 tissue factor pathway inhibitor Homo sapiens 44-48 8029788-4 1994 During hemodialysis sessions using heparin, TFPI levels increased 1.2- to 3.5-fold compared with the level before hemodialysis and the degree of increase in TFPI was correlated with the heparin concentration (r = 0.648, p = 0.0001, n = 29). Heparin 186-193 tissue factor pathway inhibitor Homo sapiens 157-161 8029788-5 1994 During dialysis sessions using low molecular weight heparin, TFPI levels also increased, but the change was less marked than during dialysis with heparin. Heparin 52-59 tissue factor pathway inhibitor Homo sapiens 61-65 8029788-7 1994 In conclusion, TFPI levels were increased by renal failure and by long-term repeated injection of heparin, but the hemodialysis procedure itself did not alter the TFPI level. Heparin 98-105 tissue factor pathway inhibitor Homo sapiens 15-19 8165616-0 1993 Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Heparin 87-95 tissue factor pathway inhibitor Homo sapiens 43-74 8165616-12 1993 It is assumed that protamine displaces heparins from the binding sites of TFPI. Heparin 39-47 tissue factor pathway inhibitor Homo sapiens 74-78 8165616-1 1993 The present study was designed to investigate the action of protamine on the release of tissue factor pathway inhibitor (TFPI) activity by unfractionated (UF) and low molecular weight (LMW) heparin in healthy individuals. Heparin 190-197 tissue factor pathway inhibitor Homo sapiens 88-119 8165616-1 1993 The present study was designed to investigate the action of protamine on the release of tissue factor pathway inhibitor (TFPI) activity by unfractionated (UF) and low molecular weight (LMW) heparin in healthy individuals. Heparin 190-197 tissue factor pathway inhibitor Homo sapiens 121-125 8292716-6 1993 Heparin and Ca2+ together, but not individually, enhance the rate of factor Xa inhibition by full-length TFPI. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 105-109 8303690-0 1993 Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis. Heparin 59-66 tissue factor pathway inhibitor Homo sapiens 0-31 8303690-0 1993 Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis. Heparin 59-66 tissue factor pathway inhibitor Homo sapiens 33-37 8473315-7 1993 In addition, plasma concentrations of both forms of TFPI, in stoichiometric complex with factor Xa, inhibited cell surface factor VIIa-tissue factor proteolytic activity markedly faster than plasma levels of antithrombin III, even in the presence of 1 unit/ml heparin. Heparin 260-267 tissue factor pathway inhibitor Homo sapiens 52-56 8259547-3 1993 TFPI was most potent in the PT assay and the effect of TFPI was most pronounced in the presence of other anticoagulants (heparin and hirudin). Heparin 121-128 tissue factor pathway inhibitor Homo sapiens 0-4 8259547-3 1993 TFPI was most potent in the PT assay and the effect of TFPI was most pronounced in the presence of other anticoagulants (heparin and hirudin). Heparin 121-128 tissue factor pathway inhibitor Homo sapiens 55-59 8259547-7 1993 In an ATIII deficient plasma heparin did not augment the effect of TFPI, showing that the increased effect of TFPI in the presence of heparin is dependent on the anticoagulant activity of ATIII/heparin. Heparin 134-141 tissue factor pathway inhibitor Homo sapiens 110-114 8259548-2 1993 In humans, injection of heparin results in a 2-6 fold increase in plasma TFPI and recent studies suggest that TFPI may be important for the anticoagulant activity of heparin. Heparin 24-31 tissue factor pathway inhibitor Homo sapiens 73-77 8259548-2 1993 In humans, injection of heparin results in a 2-6 fold increase in plasma TFPI and recent studies suggest that TFPI may be important for the anticoagulant activity of heparin. Heparin 24-31 tissue factor pathway inhibitor Homo sapiens 110-114 8259548-2 1993 In humans, injection of heparin results in a 2-6 fold increase in plasma TFPI and recent studies suggest that TFPI may be important for the anticoagulant activity of heparin. Heparin 166-173 tissue factor pathway inhibitor Homo sapiens 73-77 8259548-2 1993 In humans, injection of heparin results in a 2-6 fold increase in plasma TFPI and recent studies suggest that TFPI may be important for the anticoagulant activity of heparin. Heparin 166-173 tissue factor pathway inhibitor Homo sapiens 110-114 1420819-6 1992 Both unfractionated heparin, low-molecular-weight heparins and pentosan polysulphate induce release of TFPI after intravenous injection, whereas dermatan sulphate does not. Heparin 20-27 tissue factor pathway inhibitor Homo sapiens 103-107 8388347-2 1993 TFPI is released to the blood after injection of heparin or low molecular weight heparin (LMWH). Heparin 49-56 tissue factor pathway inhibitor Homo sapiens 0-4 8388347-2 1993 TFPI is released to the blood after injection of heparin or low molecular weight heparin (LMWH). Heparin 81-88 tissue factor pathway inhibitor Homo sapiens 0-4 8388347-4 1993 Free TFPI has higher affinity for heparin than TFPI which is associated with lipoproteins. Heparin 34-41 tissue factor pathway inhibitor Homo sapiens 5-9 8388347-5 1993 Heparin increases the rate of inactivation of FXa and of tissue factor-F VIIa by TFPI. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 81-85 8388348-0 1993 Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Heparin 76-84 tissue factor pathway inhibitor Homo sapiens 3-34 8388348-2 1993 Tissue factor pathway inhibitor (TFPI) is released into the circulation after intravenous or subcutaneous injection of heparin or low-molecular-weight heparin (Logiparin) in humans. Heparin 119-126 tissue factor pathway inhibitor Homo sapiens 0-31 8388348-2 1993 Tissue factor pathway inhibitor (TFPI) is released into the circulation after intravenous or subcutaneous injection of heparin or low-molecular-weight heparin (Logiparin) in humans. Heparin 119-126 tissue factor pathway inhibitor Homo sapiens 33-37 8388348-2 1993 Tissue factor pathway inhibitor (TFPI) is released into the circulation after intravenous or subcutaneous injection of heparin or low-molecular-weight heparin (Logiparin) in humans. Heparin 151-158 tissue factor pathway inhibitor Homo sapiens 0-31 8388348-2 1993 Tissue factor pathway inhibitor (TFPI) is released into the circulation after intravenous or subcutaneous injection of heparin or low-molecular-weight heparin (Logiparin) in humans. Heparin 151-158 tissue factor pathway inhibitor Homo sapiens 33-37 8388348-3 1993 The plasma concentration of TFPI is increased 2- to 4-fold by a prophylactic dose of Logiparin, and this excess TFPI remains in the circulation only in the presence of the heparin. Heparin 172-179 tissue factor pathway inhibitor Homo sapiens 28-32 8388348-4 1993 TFPI and heparin show strong synergism in clotting assays at concentrations obtained after heparin injection in humans. Heparin 91-98 tissue factor pathway inhibitor Homo sapiens 0-4 8388348-6 1993 It is concluded that the release of TFPI may contribute significantly to the antithrombotic effect of heparin. Heparin 102-109 tissue factor pathway inhibitor Homo sapiens 36-40 1420819-6 1992 Both unfractionated heparin, low-molecular-weight heparins and pentosan polysulphate induce release of TFPI after intravenous injection, whereas dermatan sulphate does not. Heparin 50-58 tissue factor pathway inhibitor Homo sapiens 103-107 1420819-7 1992 The interactions with TFPI account for a considerable amount of the anticoagulant effect of heparin. Heparin 92-99 tissue factor pathway inhibitor Homo sapiens 22-26 1755003-6 1991 Most likely the effect is due to the extrinsic pathway inhibitor (EPI), also called lipoprotein-associated coagulation inhibitor (LACI), which has recently been shown to be released by heparin. Heparin 185-192 tissue factor pathway inhibitor Homo sapiens 37-64 1346095-0 1992 Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Heparin 70-77 tissue factor pathway inhibitor Homo sapiens 0-44 1346095-0 1992 Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Heparin 70-77 tissue factor pathway inhibitor Homo sapiens 46-50 1346095-0 1992 Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Heparin 70-77 tissue factor pathway inhibitor Homo sapiens 120-124 1346095-3 1992 Both LACI-depleted plasma and normal plasma have identical APTTs and similar prolongations of the APTT in response to heparin; both are fully anticoagulated (arbitrarily defined as clotting times of greater than 1 hour) at similar concentrations of heparin. Heparin 118-125 tissue factor pathway inhibitor Homo sapiens 5-9 1346095-6 1992 However, in the presence of heparin, the PTs of LACI-depleted plasma and normal plasma are different. Heparin 28-35 tissue factor pathway inhibitor Homo sapiens 48-52 1346095-7 1992 Prolongation of the PT occurred only moderately and linearly with increasing concentrations of heparin in LACI-depleted plasma. Heparin 95-102 tissue factor pathway inhibitor Homo sapiens 106-110 1346095-9 1992 These results suggest that LACI serves as a cofactor for heparin and thus greatly enhances the inhibition of TF-induced coagulation. Heparin 57-64 tissue factor pathway inhibitor Homo sapiens 27-31 1346095-10 1992 LACI-depleted plasma was supplemented with purified recombinant LACI and/or heparin and the effects on TF-induced clotting were studied. Heparin 76-83 tissue factor pathway inhibitor Homo sapiens 0-4 1346095-11 1992 A combination of LACI and heparin greatly enhanced anticoagulation compared with LACI or heparin alone. Heparin 89-96 tissue factor pathway inhibitor Homo sapiens 17-21 1346095-14 1992 Based on the above results, it is concluded that LACI is a cofactor for heparin in the inhibition of TF-induced clotting and that LACI and sulfated polysaccharides act synergistically in whole plasma. Heparin 72-79 tissue factor pathway inhibitor Homo sapiens 49-53 1799658-1 1991 This study was performed in order to separate plasma fractions of tissue factor pathway inhibitor (TFPI) on the basis of TFPI"s heparin binding properties. Heparin 128-135 tissue factor pathway inhibitor Homo sapiens 66-97 1799658-1 1991 This study was performed in order to separate plasma fractions of tissue factor pathway inhibitor (TFPI) on the basis of TFPI"s heparin binding properties. Heparin 128-135 tissue factor pathway inhibitor Homo sapiens 99-103 1799658-1 1991 This study was performed in order to separate plasma fractions of tissue factor pathway inhibitor (TFPI) on the basis of TFPI"s heparin binding properties. Heparin 128-135 tissue factor pathway inhibitor Homo sapiens 121-125 1799658-4 1991 Heparin affinity chromatography separated plasma TFPI into four fractions with increasing heparin affinity: the flow-through fraction, a low affinity fraction eluting at less than 0.3 M NaCl, an intermediate affinity fraction eluting at 0.3-0.55 M NaCl and a high affinity fraction eluting at 0.55-1.0 M NaCl. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 49-53 1799658-10 1991 The anticoagulant effect of TFPI, relative to the chromogenic substrate TFPI activity, was greater in plasma fractions with high heparin affinity than in the other plasma TFPI fractions, and it was five-fold greater than the anticoagulant effect of recombinant TFPI. Heparin 129-136 tissue factor pathway inhibitor Homo sapiens 28-32 1799658-11 1991 Thus, plasma TFPI is heterogenous in heparin affinity and in anticoagulant potency. Heparin 37-44 tissue factor pathway inhibitor Homo sapiens 13-17 1664252-1 1991 Injection of heparin releases tissue factor pathway inhibitor (TFPI) to the blood and, after heparin neutralization, it has been recently demonstrated that the released TFPI has an anticoagulant activity. Heparin 13-20 tissue factor pathway inhibitor Homo sapiens 30-61 1664252-1 1991 Injection of heparin releases tissue factor pathway inhibitor (TFPI) to the blood and, after heparin neutralization, it has been recently demonstrated that the released TFPI has an anticoagulant activity. Heparin 13-20 tissue factor pathway inhibitor Homo sapiens 63-67 1664252-1 1991 Injection of heparin releases tissue factor pathway inhibitor (TFPI) to the blood and, after heparin neutralization, it has been recently demonstrated that the released TFPI has an anticoagulant activity. Heparin 13-20 tissue factor pathway inhibitor Homo sapiens 169-173 1442261-0 1992 The interaction between LACI and heparin. Heparin 33-40 tissue factor pathway inhibitor Homo sapiens 24-28 1755003-6 1991 Most likely the effect is due to the extrinsic pathway inhibitor (EPI), also called lipoprotein-associated coagulation inhibitor (LACI), which has recently been shown to be released by heparin. Heparin 185-192 tissue factor pathway inhibitor Homo sapiens 84-128 1755003-6 1991 Most likely the effect is due to the extrinsic pathway inhibitor (EPI), also called lipoprotein-associated coagulation inhibitor (LACI), which has recently been shown to be released by heparin. Heparin 185-192 tissue factor pathway inhibitor Homo sapiens 130-134 2070076-6 1991 Plasma LACI levels were elevated in women undergoing the early stages of labor (29%), in patients receiving intravenous tissue-type plasminogen activator (45%), and in patients receiving intravenous heparin (375%). Heparin 199-206 tissue factor pathway inhibitor Homo sapiens 7-11 2211593-6 1990 Transfected cells expressed 1-2 micrograms/ml of recombinant EPI (rEPI) which was purified to homogeneity by heparin-Sepharose chromatography, ion-exchange chromatography, and reverse phase high performance liquid chromatography. Heparin 109-116 tissue factor pathway inhibitor Homo sapiens 61-64 1658969-4 1991 We have earlier reported that the extrinsic pathway inhibitor (EPI) is released to the blood after heparin injection. Heparin 99-106 tissue factor pathway inhibitor Homo sapiens 34-61 2070076-7 1991 A radioligand blot of the pre- and post-heparin plasma samples shows the increase to be in a 40-Kd form of LACI. Heparin 40-47 tissue factor pathway inhibitor Homo sapiens 107-111 2070076-9 1991 Following the injection of heparin into one patient with homozygous abetalipoproteinemia, the plasma LACI antigen level increased to a level comparable with that in normal individuals after heparin treatment. Heparin 27-34 tissue factor pathway inhibitor Homo sapiens 101-105 2070076-9 1991 Following the injection of heparin into one patient with homozygous abetalipoproteinemia, the plasma LACI antigen level increased to a level comparable with that in normal individuals after heparin treatment. Heparin 190-197 tissue factor pathway inhibitor Homo sapiens 101-105 1794748-5 1991 A major pool of EPI is bound to the endothelial surface, and this fraction may be released by heparin. Heparin 94-101 tissue factor pathway inhibitor Homo sapiens 16-19 1794751-0 1991 Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Heparin 0-7 tissue factor pathway inhibitor Homo sapiens 39-66 33034200-9 2020 These studies demonstrated that IV administration of equigravemetric dosages of PMH and ovine mucosal heparin (OMH) to non-human primates resulted in comparable TFPI antigen release from endothelial cells. Heparin 102-109 tissue factor pathway inhibitor Homo sapiens 161-165 11372675-0 2001 Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Heparin 123-131 tissue factor pathway inhibitor Homo sapiens 32-63 11372675-0 2001 Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Heparin 123-131 tissue factor pathway inhibitor Homo sapiens 65-69 11372675-1 2001 The release of circulating tissue factor pathway inhibitor (TFPI) into plasma by heparins is thought to contribute to their overall antithrombotic activity. Heparin 81-89 tissue factor pathway inhibitor Homo sapiens 27-58 11372675-1 2001 The release of circulating tissue factor pathway inhibitor (TFPI) into plasma by heparins is thought to contribute to their overall antithrombotic activity. Heparin 81-89 tissue factor pathway inhibitor Homo sapiens 60-64 11372675-2 2001 In the presented study in healthy volunteers, we measured the heparin-induced increase of circulating total and free TFPI antigen and the aXa- and aIIa activity after subcutaneous (s.c.) injection of 9000 aXa-U of four different heparins: unfractionated heparin (UFH) (13.0 kDa), a medium molecular weight (MW) heparin with a narrow MW range (HF) (10.5 kDa), certoparin (6.0 kDa) and enoxaparin (4.5 kDa). Heparin 62-69 tissue factor pathway inhibitor Homo sapiens 117-121 11372675-5 2001 However, the AUC of released free TFPI significantly increased in the order: enoxaparin < UFH < certoparin < HF, showing MW dependency with the exception of UFH. Heparin 93-96 tissue factor pathway inhibitor Homo sapiens 34-38 11372675-9 2001 Although the ex vivo aIIa activity of the heparins increased in the same order like the release of free TFPI, there was no clear correlation. Heparin 42-50 tissue factor pathway inhibitor Homo sapiens 104-108 11372675-10 2001 This is attributed to the fact that the aIIa activity of heparin is not only dependent on the MW, but, in contrast to its TFPI releasing effect, also on the percentage of material with high affinity to AT. Heparin 57-64 tissue factor pathway inhibitor Homo sapiens 122-126 11372675-11 2001 In conclusion, besides the aXa- and aIIa activity, the TFPI releasing effect of heparins is an additional parameter of their individual pharmacological profile. Heparin 80-88 tissue factor pathway inhibitor Homo sapiens 55-59 32892505-12 2021 tPA, TFPI and VEGF were increased in critical patients, which are hypothesized to reflect endothelial dysfunction and/or contribution of heparin (which may cause endothelial TFPI/tPA release). Heparin 137-144 tissue factor pathway inhibitor Homo sapiens 174-178 25525049-4 2015 Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins. Heparin 68-75 tissue factor pathway inhibitor Homo sapiens 14-45 25525049-4 2015 Production of tissue factor pathway inhibitor (TFPI), a physiologic heparin-induced inhibitor of tissue factor-induced coagulation that was used as a functional readout of biological activity of enoxaparins in these assays, was heightened in the presence of branded enoxaparin complexes, but its levels were variable in cultures treated with complexes containing US-generic enoxaparins. Heparin 68-75 tissue factor pathway inhibitor Homo sapiens 47-51